Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)
","absorption":"Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.","cid":"3825","classification":"M","indications":"Ankylosing spondylitis; Arthralgia; Arthritis; Back pain; Bursitis; Contusion; Fibromyalgia; Gout; Inflammation; Ligament sprain; Musculoskeletal discomfort; Osteoarthritis; Pain; Periarthritis; Post-traumatic pain; Procedural pain; Rheumatoid arthritis; Sciatica; Spinal osteoarthritis; Spondylitis; Sports injury; Swelling; Synovitis; Tendonitis","side_effects":"Dyspepsia","atc_codes":"M01AE03; M01AE53; M02AA10","group":"Drug","drug_type":"","target":[],"function":[],"references":[]},{"compound_ID":"D0075","name":"Lamivudine","synonyms":"lamivudine; 134678-17-4; Epivir; Zeffix; Heptovir; Epivir-HBV; Hepitec; Heptodin; BCH-189; 3TC; (-)-2'-Deoxy-3'-thiacytidine; 2',3'-Dideoxy-3'-thiacytidine; GR109714X; GR-109714X; 3'-Thia-2',3'-dideoxycytidine; 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; (-)-BCH-189; CIS-LAMIVUDINE; beta-L-2',3'-Dideoxy-3'-thiacytidine; beta-L-3'-Thia-2',3'-dideoxycytidine; (-)NGPB-21; (-)-BCH 189; 136891-12-8; UNII-2T8Q726O95; HSDB 7155; GR 109714X; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; BCH 189, (-)-; C8H11N3O3S; CHEBI:63577; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 2T8Q726O95; CPD000466319; Heptivir; Lamivir; Zefix; 2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-; BCH 189; Lamivudine [USAN:BAN:INN]; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; 2(1H)-Pyrimidinone, 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-; 4-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-2(1H)-PYRIMIDINONE; Epivir(TM); HHA & Lamivudine; Lamivudine & GNA; SMR000466319; Lamivudine [USAN:INN:BAN]; Epivir (TN); DTHC; CHEMBL141; DRG-0126; 3TC and NV-01; (-)-SddC; Lamivudina; Lamivudinum; Lamivudin; Lamivudine (JAN/USP/INN); 3TC & GNA; 3TC & SST; HHA & 3TC; (+/-)-SddC; CCRIS 9274; NSC620753; 2(1H)-Pyrimidinone, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-; BCH-790; Lamivudine [USAN:USP:INN:BAN]; Lamivudine(Epivir); NCGC00159341-04; Lamivudine, 98%; GG-714; Lamivudine (EPIVIR); (+/-)-3TC; (+/-)-BCH-189; 3TC (AIDS INITIATIVE) (AIDS INITIATIVE); MLS000759424; MLS001424097; MLS006011910; BIDD:GT0033; SCHEMBL109675; PYR356; CTK3J2124; ZINC12346; JTEGQNOMFQHVDC-NKWVEPMBSA-N; HMS2051D21; HMS3259F08; HMS3713C16; 480434-79-5; HY-B0250; ANW-43098; BBL033871; BDBM50366817; MFCD00869739; s1706; SBB066293; STK801940; lamivudine & TNF-alpha & IFN-gamma; AKOS005622556; AKOS015854841; Lamivudine, >=98% (HPLC), powder; AB07588; AC-1416; CCG-100984; CS-2230; DB00709; KS-1073; LS-2107; MCULE-2096184994; NC00234; NC00705; RTC-020973; (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; KS-0000023D; NCGC00159341-05; 4-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-1,2-DIHYDROPYRIMIDIN-2-ONE; LMV; SAM001246582; SAM002589994; SC-15184; FT-0082667; FT-0601626; FT-0650554; L0217; ST24030826; SW197614-3; C07065; D00353; J10244; M-9795; 24222-EP2269989A1; 24222-EP2272516A2; 24222-EP2272825A2; 24222-EP2292227A2; 24222-EP2298761A1; 24222-EP2298783A1; 24222-EP2305243A1; 24222-EP2305640A2; 24222-EP2305680A2; 24222-EP2314590A1; AB00639995-06; AB00639995-08; AB00639995_09; 200973-EP2272825A2; 678L174; Q422631; SR-01000759420; J-700183; Q-201275; SR-01000759420-5; Lamivudine, British Pharmacopoeia (BP) Reference Standard; Lamivudine, European Pharmacopoeia (EP) Reference Standard; (2R,5S)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; .beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; Lamivudine, United States Pharmacopeia (USP) Reference Standard; (+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-L-2',3'-DIDEOXY-3'-THIACYTIDINE; LAMIVUDINE; EPIVIR; Lamivudine, 1.0 mg/mL in methanol, certified reference material; Lamivudine, Pharmaceutical Secondary Standard; Certified Reference Material; (+/-)-(cis)-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis); 3-[(5S,2R)-2-(hydroxymethyl)(1,3-oxathiolan-5-yl)]-6-amino-3-hydropyrimidin-2- one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-[1,3]-oxathiolan-5-yl]-(1H)-pyrimidin-2-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-Oxathiolan-5-yl]-(1H)-pyrimidin-2-one; cis(+/-)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; Lamivudine for system suitability 1, European Pharmacopoeia (EP) Reference Standard; Lamivudine for system suitability 2, European Pharmacopoeia (EP) Reference Standard; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA)","trade_name":"Epivir","abbrev_name":"3TC, 2',3'-dideoxy-3'-thiacytidine","description":"Antiviral; analogue of cytidine","molecular_formula":"C8H11N3O3S","molecular_weight":"229.26","state":"solid","clearance":"* Renal clearance = 199.7 ± 56.9 mL/min [300 mg oral dose, healthy subjects] \n* Renal clearance = 280.4 ± 75.2 mL/min [single IV dose, HIV-1-infected patients]\n* Total clearance = 398.5 ± 69.1 mL/min [HIV-1-infected patients]","volume_of_distribution":"Apparent volume of distribution, IV administration = 1.3 ± 0.4 L/kg. Volume of distribution was independent of dose and did not correlate with body weight.","route_of_elimination":"The majority of lamivudine is eliminated unchanged in urine by active organic cationic secretion. 5.2% ± 1.4% (mean ± SD) of the dose was excreted as the trans-sulfoxide metabolite in the urine. Lamivudine is excreted in human breast milk and into the milk of lactating rats.","protein_binding":"<36% bound to plasma protein.","half_life":"5 to 7 hours (healthy or HBV-infected patients)","absorption":"Lamivudine was rapidly absorbed after oral administration in HIV-infected patients. Absolute bioavailability in 12 adult patients was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the oral solution. The peak serum lamivudine concentration (Cmax) was 1.5 ± 0.5 mcg/mL when an oral dose of 2 mg/kg twice a day was given to HIV-1 patients. When given with food, absorption is slower, compared to the fasted state.","cid":"60825","classification":"J","indications":"Alanine aminotransferase increased; Chronic hepatitis B; Fibrosis; Foetor hepaticus; Hepatic failure; Hepatitis B; Hepatitis B DNA decreased; Hepatitis B e antigen positive; Hepatitis B surface antigen positive; Hepatitis C; Hepatitis chronic active; Hepatitis D; Hepatitis viral; Hepatocellular injury; Immunodeficiency; Infection; Inflammation; Liver disorder; Pancreatitis; Pathogen resistance; Viral infection","side_effects":"Abdominal distension (0.03); Pruritus (0.01); Abdominal discomfort; Abdominal pain; Acne; Anaemia; Asthenia; Blood creatine phosphokinase increased; Body temperature increased; Breath sounds abnormal; Bronchitis; Cough; Decreased appetite; Dermatitis; Diarrhoea; Discomfort; Dizziness; Dyspepsia; Fatigue; Feeling abnormal; Folliculitis; Fungal skin infection; Gastrointestinal infection; Gastrointestinal pain; Headache; Hepatomegaly; Hyperhidrosis; Ill-defined disorder; Infection; Inflammation; Liver function test abnormal; Lymphadenopathy; Malaise; Musculoskeletal discomfort; Musculoskeletal pain; Myalgia; Nasopharyngitis; Nausea; Neuropathy peripheral; Neutropenia; Oropharyngeal discomfort; Oropharyngeal pain; Pain; Pharyngitis; Rash; Respiration abnormal; Respiratory disorder; Respiratory tract infection; Rhinorrhoea; Sinusitis; Sleep disorder; Splenomegaly; Stomatitis; Thrombocytopenia; Viral infection; Viral skin infection; Vomiting; Wheezing","atc_codes":"J05AR24; J05AR16; J05AR12; J05AF05; J05AR13; J05AR04; J05AR02; J05AR07; J05AR01; J05AR05; J05AR11","group":"Drug","drug_type":"","target":["T001","T002","T234","T408"],"function":["F0108","F0201","F0303","F060102"],"references":["RC03677","RC04079","RC04203","RC04327","RC04451","RC04575"]},{"compound_ID":"D0076","name":"Lidocaine","synonyms":"lidocaine; 137-58-6; Lignocaine; Xylocaine; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; Lidoderm; Anestacon; Esracaine; Duncaine; Alphacaine; Cappicaine; Gravocain; Isicaina; L-Caine; Leostesin; Maricaine; Xylocain; Xylocitin; Solcain; Isicaine; Xylestesin; Rucaina; Xilina; Xycaine; Xylotox; Cito optadren; Lida-Mantle; Dalcaine; 2-(Diethylamino)-2',6'-acetoxylidide; Xyloneural (free base); Cuivasil; Dentipatch; Jetocaine; Lignocainum; Octocaine; Remicaine; Xilocaina; Xllina; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide; Lidocaine (VAN); Diethylaminoaceto-2,6-xylidide; ELA-Max; Xilocaina [Italian]; Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-; alpha-Diethylamino-2,6-dimethylacetanilide; Lidocainum [INN-Latin]; Lidocaina [INN-Spanish]; EMBOLEX; 2',6'-Acetoxylidide, 2-(diethylamino)-; Lidocaton; alfa-Dietilamino-2,6-dimetilacetanilide; CHEBI:6456; HSDB 3350; UNII-98PI200987; Xylocaine (TN); CHEMBL79; EINECS 205-302-8; NSC 40030; LIDOPEN; alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; BRN 2215784; C14H22N2O; MLS000069724; NNJVILVZKWQKPM-UHFFFAOYSA-N; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; .alpha.-Diethylaminoaceto-2,6-xylidide; NCGC00015611-10; Xylesthesin; Dilocaine; Lidocaina; Lidocaine, 97.5%; Lidocainum; SMR000058189; .alpha.-(Diethylamino)-2,6-acetoxylidide; .alpha.-Diethylamino-2,6-dimethylacetanilide; .omega.-Diethylamino-2,6-dimethylacetanilide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)-acetamide; 98PI200987; DSSTox_CID_25166; DSSTox_RID_80716; DSSTox_GSID_45166; N-(2,6-Dimethylphenyl)-N2,N2-diethylglycinamide; 2-(Diethylamino)-N-(2,6-Dimethylphenyl)ethanamide; Lidocaine Hydrocarbonate; Versatis; Ztilido; Lidocaine Base; ZTlido; Lidocaine Monohydrochloride; Xylocaine CO2; Dentipatch (TN); CAS-137-58-6; LQZ; Lidocaine [USAN:INN:JAN]; Qualigens; Xyline; Lignocaine base; LidocaineHClH2O; Lidocaine [USP:INN:BAN:JAN]; Lidocaine, powder; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; Zingo (Salt/Mix); MFCD00026733; Lidocaine(Alphacaine); CDS1_000283; Lidocaine (Alphacaine); Spectrum_001118; Lidothesin (Salt/Mix); Xyloneural (Salt/Mix); Opera_ID_385; Maybridge1_002571; Prestwick0_000050; Prestwick1_000050; Prestwick2_000050; Prestwick3_000050; Spectrum2_001343; Spectrum3_001392; Spectrum4_000070; Spectrum5_001549; Lopac-L-5647; Lidaform HC (Salt/Mix); Epitope ID:116205; Lidamantle HC (Salt/Mix); 2', 2-(diethylamino)-; Neosporin Plus (Salt/Mix); Lopac0_000669; SCHEMBL15689; BSPBio_000179; BSPBio_001359; BSPBio_003004; KBioGR_000079; KBioGR_000599; KBioSS_000079; KBioSS_001598; 4-12-00-02538 (Beilstein Handbook Reference); MLS000758263; MLS001074177; MLS001423964; N1-(2,6-dimethylphenyl)-N2,N2-diethylglycinamide; ARONIS23855; BIDD:GT0342; Diethylaminoacet-2,6-xylidide; DivK1c_000174; DivK1c_001323; Lidocaine, analytical standard; Alphacaine;Xylocaine;lignocaine; SPBio_001525; SPBio_002100; Lidocaine (JP17/USP/INN); BPBio1_000197; GTPL2623; DTXSID1045166; SCHEMBL17967359; CTK3J2126; HMS548M19; KBio1_000174; KBio2_000079; KBio2_001598; KBio2_002647; KBio2_004166; KBio2_005215; KBio2_006734; KBio3_000157; KBio3_000158; KBio3_002224; ZINC20237; Lidocaine 1.0 mg/ml in Methanol; NINDS_000174; Bio1_000379; Bio1_000868; Bio1_001357; Bio2_000079; Bio2_000559; HMS1791D21; HMS1989D21; HMS2051C21; HMS2089E15; HMS2235O14; HMS3371J04; HMS3393C21; HMS3428O07; HMS3651G09; BCP09081; HY-B0185; KS-000046GY; NSC40030; Tox21_110183; ANW-42187; BBL005525; BDBM50017662; LS-805; NSC-40030; s1357; SBB080556; STK552033; AKOS001026768; Tox21_110183_1; CCG-100824; CS-2070; DB00281; MCULE-9294700940; NC00074; RTR-031283; SB19118; WLN: 2N2 & 1VMR B1 F1; .alpha.-Diethylamino-2,6-acetoxylidide; CAS-73-78-9; IDI1_000174; IDI1_033829; NCGC00015611-01; NCGC00015611-02; NCGC00015611-03; NCGC00015611-04; NCGC00015611-05; NCGC00015611-06; NCGC00015611-07; NCGC00015611-08; NCGC00015611-09; NCGC00015611-11; NCGC00015611-12; NCGC00015611-13; NCGC00015611-14; NCGC00015611-15; NCGC00015611-16; NCGC00015611-18; NCGC00022176-05; NCGC00022176-06; NCGC00022176-07; NCGC00022176-08; NCGC00022176-09; AC-10282; AS-13718; CPD000058189; M620; SAM001247018; SC-19460; ST023341; 2-(Diethylamino)-2'',6''-acetoxylidide; SBI-0050648.P004; AB2000065; Lignocaine base 100 microg/mL in Methanol; TR-031283; AB00053581; FT-0082378; FT-0600570; L0156; SW196598-4; A18187; C07073; D00358; J10173; K-4450; AB00053581-27; AB00053581-28; AB00053581_29; AB00053581_30; Q216935; (2,6-dimethylphenyl)carbamoylmethyl-diethyl-azanium; N1-(2,6-dimethylphenyl)-2-(diethylamino)acetamide; W-108233; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide #; BRD-K52662033-001-02-6; BRD-K52662033-003-05-5; BRD-K52662033-003-14-7; Z55135799; Lidocaine, British Pharmacopoeia (BP) Reference Standard; Lidocaine, European Pharmacopoeia (EP) Reference Standard; N~1~-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; Lidocaine, United States Pharmacopeia (USP) Reference Standard; Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material; Lidocaine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; 91484-71-8; LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE); 6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))","trade_name":"Xylocaine","abbrev_name":"","description":"Local anesthetics","molecular_formula":"C14H22N2O","molecular_weight":"234.34","state":"solid","clearance":"The mean systemic clearance observed for intravenously administered lidocaine in a study of 15 adults was approximately 0.64 +/- 0.18 L/min [F4444].","volume_of_distribution":"The volume of distribution determined for lidocaine is 0.7 to 1.5 L/kg [L5948].\n\nIn particular, lidocaine is distributed throughout the total body water [L5930]. Its rate of disappearance from the blood can be described by a two or possibly even three-compartment model [L5930]. There is a rapid disappearance (alpha phase) which is believed to be related to uptake by rapidly equilibrating tissues (tissues with high vascular perfusion, for example) [L5930]. The slower phase is related to distribution to slowly equilibrating tissues (beta phase) and to its metabolism and excretion (gamma phase) [L5930].\n\nLidocaine's distribution is ultimately throughout all body tissues [L5930]. In general, the more highly perfused organs will show higher concentrations of the agent [L5930]. The highest percentage of this drug will be found in skeletal muscle, mainly due to the mass of muscle rather than an affinity [L5930].","route_of_elimination":"The excretion of unchanged lidocaine and its metabolites occurs predominantly via the kidney with less than 5% in the unchanged form appearing in the urine [F4349, L5930]. The renal clearance is inversely related to its protein binding affinity and the pH of the urine [L5930]. This suggests by the latter that excretion of lidocaine occurs by non-ionic diffusion [L5930].","protein_binding":"The protein binding recorded for lidocaine is about 60 to 80% and is dependent upon the plasma concentration of alpha-1-acid glycoprotein [F4349, L5948]. Such percentage protein binding bestows lidocaine with a medium duration of action when placed in comparison to other local anesthetic agents [L5948].","half_life":"The elimination half-life of lidocaine hydrochloride following an intravenous bolus injection is typically 1.5 to 2.0 hours [F4349]. Because of the rapid rate at which lidocaine hydrochloride is metabolized, any condition that affects liver function may alter lidocaine HCl kinetics [F4349]. The half-life may be prolonged two-fold or more in patients with liver dysfunction [F4349].","absorption":"In general, lidocaine is readily absorbed across mucous membranes and damaged skin but poorly through intact skin [F4468]. The agent is quickly absorbed from the upper airway, tracheobronchial tree, and alveoli into the bloodstream [F4468]. And although lidocaine is also well absorbed across the gastrointestinal tract the oral bioavailability is only about 35% as a result of a high degree of first-pass metabolism [F4468]. After injection into tissues, lidocaine is also rapidly absorbed and the absorption rate is affected by both vascularity and the presence of tissue and fat capable of binding lidocaine in the particular tissues [F4468].\n\nThe concentration of lidocaine in the blood is subsequently affected by a variety of aspects, including its rate of absorption from the site of injection, the rate of tissue distribution, and the rate of metabolism and excretion [F4349, L5930, L5948]. Subsequently, the systemic absorption of lidocaine is determined by the site of injection, the dosage given, and its pharmacological profile [F4349, L5930, L5948]. The maximum blood concentration occurs following intercostal nerve blockade followed in order of decreasing concentration, the lumbar epidural space, brachial plexus site, and subcutaneous tissue [F4349, L5930, L5948]. The total dose injected regardless of the site is the primary determinant of the absorption rate and blood levels achieved [F4349, L5930, L5948]. There is a linear relationship between the amount of lidocaine injected and the resultant peak anesthetic blood levels [F4349, L5930, L5948].\n\nNevertheless, it has been observed that lidocaine hydrochloride is completely absorbed following parenteral administration, its rate of absorption depending also on lipid solubility and the presence or absence of a vasoconstrictor agent [F4349, L5930, L5948]. Except for intravascular administration, the highest blood levels are obtained following intercostal nerve block and the lowest after subcutaneous administration [F4349, L5930, L5948].\n\nAdditionally, lidocaine crosses the blood-brain and placental barriers, presumably by passive diffusion [F4349].","cid":"3676","classification":"S; D; R; C; N","indications":"Acute coronary syndrome; Acute myocardial infarction; Agitation; Anal fissure; Anal pruritus; Anorectal discomfort; Arrhythmia; Arthropod bite; Bladder pain; Cardiac arrest; Cardiovascular insufficiency; Cystitis; Cystitis noninfective; Discomfort; Eczema; Haemorrhoids; Herpes zoster; Myocardial infarction; Oesophagitis; Oropharyngeal discomfort; Oropharyngeal pain; Pain; Photosensitivity reaction; Post gastric surgery syndrome; Post herpetic neuralgia; Pruritus; Pruritus genital; Retching; Sunburn; Tenderness; Toxicity to various agents; Urethritis; Urethritis noninfective; Ventricular arrhythmia; Vulvovaginal pruritus","side_effects":"Nausea (0.02); Vomiting (0.01)","atc_codes":"C05AD01; C01BB01; S02DA01; R02AD02; D04AB01; N01BB02; S01HA07; N01BB52","group":"Drug","drug_type":"","target":["T001","T408"],"function":["F0101","F0108","F0201","F02010202","F02040101","F0303"],"references":["RC00538","RC00539","RC03644","RC04080","RC04204","RC04328","RC04452","RC04576"]},{"compound_ID":"D0077","name":"Linezolid","synonyms":"linezolid; 165800-03-3; Zyvox; (S)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide; Zyvoxid; PNU-100766; Zyvoxam; U-100766; PNU 100766; U 100766; UNII-ISQ9I6J12J; C16H20FN3O4; HSDB 7478; CHEMBL126; ISQ9I6J12J; N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide; CHEBI:63607; TYZROVQLWOKYKF-ZDUSSCGKSA-N; Linezolid, 98%; CPD000466335; (S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-; N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide; N-{[(5s)-3-(3-Fluoro-4-Morpholin-4-Ylphenyl)-2-Oxo-1,3-Oxazolidin-5-Yl]methyl}acetamide; Q-201308; LINEZOLIDE; Zivoxid; Zyvoxa; Linezolid [USAN:INN]; (S)-N-[[3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; Acetamide, N-(((5S)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-; Acetamide, N-((3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-, (S)-; N-[[(5S)-3-(3-fluoro-4-morpholino-phenyl)-2-oxo-oxazolidin-5-yl]methyl]acetamide; N-[[(5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide; SMR000466335; ZLD; Zyvox (TN); SR-01000759376; Linezolid & VRC3375; Linezolidum; Linezoid; Linezolid (JAN/USAN/INN); Linezolid [USAN:INN:BAN]; Linezolid(Zyvox); NCGC00164628-01; Linezolid (Zyvox); AK105905; N-({(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide; N-{[(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide; 111GE017; NDA 21-130 Zyvox (linezolid tablets); N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; SCHEMBL5027; DSSTox_CID_26489; DSSTox_RID_81660; DSSTox_GSID_46489; MLS000759444; MLS001424075; BIDD:GT0404; Benzotriazol-2-yl-acetonitrile; cid_441401; Linezolid (PNU-100766); QCR-88; DTXSID5046489; Linezolid, >=98% (HPLC); NDA 21-131 Zyvox for injection (linezolid injection); SYN3021; HMS2051F08; HMS2089K06; HMS3260C14; HMS3713K10; NDA 21-132 Zyvox oral suspension (linzolid oral suspension); BCP05586; KS-00000BB5; ZINC2008866; Tox21_112246; Tox21_500096; BDBM50116067; GA2609; MFCD00937825; s1408; AKOS016340522; AM84567; BCP9000855; CCG-101009; CS-0756; DB00601; KS-1178; NC00259; NCGC00260781-01; NCGC00263531-03; NCGC00263531-10; CC-29960; HY-10394; N-({5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, N-[[(S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; SAM001246624; SC-11638; AB0012049; AX8042607; LS-173594; ST2408359; CAS-165800-03-3; FT-0080803; FT-0602524; SW197639-3; C08146; D00947; J90009; M-8338; AB00639994-06; AB00639994-08; AB00639994-09; AB00639994_10; AB00639994_11; 800L033; A810662; C-20237; Q411377; SR-01000759376-4; SR-01000759376-5; U-100,766; Linezolid, United States Pharmacopeia (USP) Reference Standard; (S)-N-((3-fluoro-4-morpholinophenyl)-2-oxaoxazolidin-5-yl)methyl)acetamide; Linezolid, Pharmaceutical Secondary Standard; Certified Reference Material; (Linezolid)N-[3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide; (R)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide; (S)-N-((3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; (S)-N-[ [3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-oxazolidin-5-yl]methyl]-acetamide; (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide; N-[(R)-3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide; N-[(S)-3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide; N-[3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide; N-[3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide(linezolid); (S)-3-(3-Fluoro-4-morpholin-4-yl-phenyl)-5-[(1-hydroxy-ethylamino)-methyl]-oxazolidin-2-one; N-((S)-2-oxo-3-(S)-2,3,3a,4-tetrahydro-1H-benzo[b]pyrrolo[1,2-d][1,4]oxazin-7-yl-oxazolidin-5-ylmethyl)-acetamide; N-[[(5S)-3-(3-fluoranyl-4-morpholin-4-yl-phenyl)-2-oxidanylidene-1,3-oxazolidin-5-yl]methyl]ethanamide","trade_name":"Zyvox, Zyvoxid","abbrev_name":"","description":"Antibacterial; oxazolidinone class","molecular_formula":"C16H20FN3O4","molecular_weight":"337.35","state":"solid","clearance":"","volume_of_distribution":"* 40 to 50 L [healthy adult volunteers]","route_of_elimination":"","protein_binding":"0.31","half_life":"4.5-5.5 hours","absorption":"Linezolid is rapidly and extensively absorbed after oral dosing. Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.","cid":"441401","classification":"J","indications":"Bacteraemia; Cellulitis gangrenous; Decubitus ulcer; Diabetes mellitus; Diabetic foot infection; Infection; Necrotising fasciitis; Osteomyelitis; Urinary tract infection","side_effects":"Abdominal pain; Anaemia; Anaphylactic shock; Apnoea; Body temperature increased; Candida infection; Constipation; Convulsion; Cough; Dermatitis; Diarrhoea; Dizziness; Dysgeusia; Dyspnoea; Eosinophilia; Fluid retention; Fungal infection; Gastrointestinal haemorrhage; Gastrointestinal pain; Generalised oedema; Headache; Hypokalaemia; Injury; Insomnia; Liver function test abnormal; Nausea; Oral candidiasis; Pain; Pharyngitis; Pneumonia; Pruritus; Rash; Sepsis; Skin disorder; Thrombocytopenia; Thrombocytosis; Tongue discolouration; Upper respiratory tract infection; Vertigo; Vomiting; Vulvovaginal candidiasis; Vulvovaginal mycotic infection","atc_codes":"J01XX08","group":"Drug","drug_type":"","target":["T001","T002","T004","T005","T019"],"function":["F020103","F0604"],"references":["RC00152","RC00153","RC00154","RC00155","RC00156","RC03616","RC03827","RC03832","RC03882"]},{"compound_ID":"D0078","name":"Mefenamic acid","synonyms":"mefenamic acid; 61-68-7; Ponstel; 2-[(2,3-dimethylphenyl)amino]benzoic acid; Ponstan; Mephenamic acid; Parkemed; Coslan; Mefacit; Ponalar; Methenamic acid; Mephenaminic acid; Bonabol; Lysalgo; Tanston; Vialidon; 2-((2,3-Dimethylphenyl)amino)benzoic acid; Bafameritin-M; Tamany Bonsan; Acide mefenamique; Mefenaminsaeure; Ponstan forte; Namphen; Pontal; Mefanamic acid; Bafhameritin-M; CN-35355; Mefenacid; Ponstil; Ponstyl; Acido mefenamico; Acidum mefenamicum; HL 1; 2-(2,3-Dimethylanilino)benzoic acid; Mefedolo; Mycasaal; N-2,3-Xylylanthranilic acid; Rolan; INF 3355; INF-3355; N-(2,3-Xylyl)anthranilic acid; N-(2,3-Dimethylphenyl)anthranilic acid; AGN-1255; CI-473; CL 473; N-(2,3-Xylyl)-2-aminobenzoic acid; Mefenaminsaeure [German]; Ac. mefenamico [Italian]; Acide mefenamique [French]; Acide mefenamique [INN-French]; Acido mefenamico [INN-Spanish]; Acidum mefenamicum [INN-Latin]; Benzoic acid, 2-[(2,3-dimethylphenyl)amino]-; Anthranilic acid, N-2,3-xylyl-; CN 35355; NSC 94437; 2-(2,3-dimethylphenylamino)benzoic acid; UNII-367589PJ2C; HSDB 3115; EINECS 200-513-1; Benzoic acid, 2-((2,3-dimethylphenyl)amino)-; CI 473; 2-Diphenylaminecarboxylic acid, 2',3'-dimethyl-; CHEMBL686; BRN 2216243; MLS000069709; CHEBI:6717; HYYBABOKPJLUIN-UHFFFAOYSA-N; NSC94437; Anthranilic acid, N-(2,3-xylyl)-; 367589PJ2C; CAS-61-68-7; NCGC00016278-07; CPD000058188; SMR000058188; Benzoic acid, 2-(2,3-dimethylphenyl)amino-; DSSTox_CID_3243; DSSTox_RID_76938; DSSTox_GSID_23243; in-M; Mefenamicacid; 2-(2,3-Xylidino)benzoic Acid; SR-01000000216; Mefenaminsaure; mefenamic-acid; Prestwick_506; MFCD00051721; Mefenamic Acid,(S); Spectrum_000174; Opera_ID_542; Mefenamic acid [USAN:USP:INN:BAN:JAN]; Prestwick0_000054; Prestwick1_000054; Prestwick2_000054; Prestwick3_000054; Spectrum2_001941; Spectrum3_001082; Spectrum4_001235; Spectrum5_001341; M1782; Anthranilic acid,3-xylyl-; cid_4044; SCHEMBL3544; Oprea1_193889; BSPBio_000207; BSPBio_002724; KBioGR_001730; KBioSS_000654; MLS001074162; DivK1c_000298; SPECTRUM1501103; SPBio_002001; SPBio_002128; BPBio1_000229; F0850-6853; GTPL2593; SGCUT00005; WLN: QVR BMR B1 C1; DTXSID5023243; HMS500O20; KBio1_000298; KBio2_000654; KBio2_003222; KBio2_005790; KBio3_001944; KS-00000WDA; ZINC20241; BRD8217; NINDS_000298; CI 473 pound notCN-35355; HMS1568K09; HMS1921D13; HMS2090B07; HMS2092B17; HMS2095K09; HMS2232P18; HMS3259M19; HMS3370K18; HMS3652A10; HMS3712K09; Pharmakon1600-01501103; Mefenamic acid (JP17/USP/INN); Mefenamic acid, analytical standard; ALBB-025759; BCP08499; BRD-8217; HY-B0574; to_000071; Tox21_110344; Tox21_301983; BBL003564; BDBM50134036; CCG-39434; NSC-94437; NSC757834; s4078; SBB056999; STK666691; AKOS001025551; AKOS002388313; Benzoic acid,3-dimethylphenyl)amino]-; Tox21_110344_1; CS-2681; DB00784; MCULE-1031776135; NC00517; NSC-757834; IDI1_000298; SMP2_000141; 2-(2,3-Dimethylanilino)benzoic acid #; NCGC00016278-01; NCGC00016278-02; NCGC00016278-03; NCGC00016278-04; NCGC00016278-05; NCGC00016278-06; NCGC00016278-10; NCGC00022393-03; NCGC00022393-04; NCGC00022393-05; NCGC00255401-01; AC-11160; AK-72920; AS-12677; BR-72920; LS-20589; SAM002554908; SC-16204; ST086740; SBI-0051636.P002; 2-(2,3-Dimethyl-phenylamino)-benzoic acid; AB0012318; AB1009470; ST2409237; 2-[(2,3-dimethylphenyl) amino]benzoic acid; 2-Diphenylaminecarboxylic acid,3'-dimethyl-; AB00052200; AM20060688; FT-0628184; SW196700-3; UNM000001233403; C02168; D00151; M-6454; AB00052200-17; AB00052200_18; AB00052200_19; A833367; Q284321; SR-01000000216-2; SR-01000000216-4; W-105113; BRD-K92778217-001-06-1; Z56755828; 2-(2,3-Dimethyl-phenylamino)-benzoic acid(Mefenamic acid); Mefenamic acid, European Pharmacopoeia (EP) Reference Standard; Mefenamic acid, United States Pharmacopeia (USP) Reference Standard; 4-methyl-N-(3-{3-[(4-methylpiperidin-1-yl)carbonyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)benzenesulfonamide; InChI=1/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18","trade_name":"","abbrev_name":"","description":"anthranilic acid derivatives class of nonsteroidal anti-inflammatory drugs","molecular_formula":"C15H15NO2","molecular_weight":"241.28","state":"solid","clearance":"* Oral cl=21.23 L/hr [Healthy adults (18-45 yrs)]","volume_of_distribution":"* 1.06 L/kg [Normal Healthy Adults (18-45 yr)]","route_of_elimination":"The fecal route of elimination accounts for up to 20% of the dose, mainly in the form of unconjugated 3-carboxymefenamic acid.3 The elimination half-life of mefenamic acid is approximately two hours. Mefenamic acid, its metabolites and conjugates are primarily excreted by the kidneys. Both renal and hepatic excretion are significant pathways of elimination.","protein_binding":"0.9","half_life":"2 hours","absorption":"Mefenamic acid is rapidly absorbed after oral administration.","cid":"4044","classification":"M","indications":"Body temperature increased; Diabetes mellitus; Dysmenorrhoea; Menorrhagia; Metrorrhagia; Pain; Toothache","side_effects":"","atc_codes":"M01AG01","group":"Drug","drug_type":"","target":["T001","T002","T408"],"function":["F01","F0108","F0201","F02010102","F02010103","F0206","F0221","F0303","F0504","F070105","F070106"],"references":["RC04085","RC04209","RC04333","RC04457","RC04581","RC04767","RC04780","RC04793","RC04806","RC04819","RC04832","RC04845","RC04858"]},{"compound_ID":"D0079","name":"Meloxicam","synonyms":"meloxicam; 71125-38-7; Mobic; Metacam; Movalis; Mobicox; Meloxicam (Mobic); Mobec; Meloxicamum; Movatec; Parocin; Meloxicamum [Latin]; UH-AC 62XX; 4-Hydroxy-2-methyl-N-(5-methylthiazol-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; UNII-VG2QF83CGL; UHAC-62XX; CCRIS 9139; C14H13N3O4S2; VG2QF83CGL; CHEMBL599; 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; MLS000028587; CHEBI:6741; miloxicam; NCGC00018248-04; AK-77454; SMR000058994; DSSTox_CID_803; Meloxicam, 99-101%; 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; DSSTox_RID_75796; DSSTox_GSID_20803; Revmoksikam; Coxflam; Coxicam; Melonex; Meloxivet; Tenaron; Vivlodex; Melfax; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methylthiazolyl)-, 1,1-dioxide; (E)-3-(hydroxy((5-methylthiazol-2-yl)amino)methylene)-2-methyl-2,3-dihydro-4H-benzo[e][1,2]thiazin-4-one 1,1-dioxide; 1027136-06-6; 133687-22-6; CAS-71125-38-7; HSDB 7741; Meloxicam(Mobic); Meloxicam [USAN:USP:INN:BAN]; Meloxicam,(S); 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1?^{6},2-benzothiazine-3-carboxamide; MXM; Mobic (TN); Opera_ID_2; Spectrum_001633; Spectrum2_000941; Spectrum3_000649; Spectrum4_000787; Spectrum5_001813; SCHEMBL3576; Lopac0_000766; SCHEMBL33369; BSPBio_002257; KBioGR_001234; KBioSS_002113; Meloxicam (JAN/USAN/INN); Meloxicam [USAN:BAN:INN]; MLS001304725; MLS001306413; MLS006011422; BIDD:GT0726; SCHEMBL713100; SPECTRUM1504150; SPBio_000902; GTPL7220; CHEMBL1741042; DTXSID1020803; CTK6C3599; CTK6C3600; KBio2_002113; KBio2_004681; KBio2_007249; KBio3_001477; ETI-511; ZRVUJXDFFKFLMG-UHFFFAOYSA-N; HMS1922D19; HMS2089B18; HMS2096I19; HMS2234P07; HMS2236C09; HMS3259H06; HMS3372C13; HMS3372P18; HMS3655K06; HMS3713I19; HMS3744K09; ALBB-027268; BB_SC-04648; BCP11928; HY-B0261; KS-00000JN4; ZX-AN025777; Tox21_111734; Tox21_113192; Tox21_201689; Tox21_302756; ANW-57553; BBL029076; BDBM50056998; BG0248; CCG-39098; HSCI1_000045; MFCD00868752; s1734; STK620505; ZINC13129998; AKOS000279442; AKOS026749959; Tox21_111734_1; ZINC103620661; AC-1325; CS-2247; DB00814; KS-1084; MCULE-4138373089; NC00698; RTR-031220; 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazoyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; SMP2_000133; NCGC00018248-01; NCGC00018248-02; NCGC00018248-03; NCGC00018248-05; NCGC00018248-06; NCGC00018248-07; NCGC00018248-08; NCGC00022924-03; NCGC00022924-04; NCGC00256316-01; NCGC00259238-01; NCGC00263878-02; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide; CC-30198; CPD000718800; LS-40538; SAM002589991; SC-12165; SMR000718800; AB0007297; AB1009494; DB-055490; Meloxicam 1.0 mg/ml in Dimethyl Sulfoxide; FT-0082769; FT-0628193; M1959; R3928; ST24023559; SW219562-1; EN300-52507; C08169; D00969; J10218; N-1539; AB00383033-17; AB00383033-18; AB00383033_20; 125M387; A837087; AN-668/13244001; C-20653; Q414028; SR-01000003132-10; F2173-0387; Z1695493323; 4-hydroxy-2-methyl-N-(5-methy-2-thiazolyl)-2H-1,2-benzothiazine-3-caboxamide-1,1-dioxide; (3Z)-2-methyl-3-[[(5-methyl-1,3-thiazol-2-yl)amino]-oxidanyl-methylidene]-1,1-bis(oxidanylidene)-1$l^{6},2-benzothiazin-4-one; (3Z)-3-[hydroxy-[(5-methyl-2-thiazolyl)amino]methylidene]-2-methyl-1,1-dioxo-1$l^{6},2-benzothiazin-4-one; 3-{hydroxy[(5-methyl-1,3-thiazol-2-yl)amino]methylidene}-2-methyl-2,3-dihydro-4H-1,2-benzothiazin-4-one 1,1-dioxide; 4-Hydroxy-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide; 4-hydroxy-2-mehtyl-N-(5-mehtyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-Hydroxy-2-methyl-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1$l^{6},2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1$l^{6},2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1lambda6,2-benzothiazine-3-carboxamide; 4-Hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazin-3-crboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(5-methyl-2-thiazole)-2H-1,2-benzothiazine-3 -carboxamide 1,1-dioxide","trade_name":"Mobic","abbrev_name":"","description":"nonsteroidal anti-inflammatory drug (NSAID); blocks cyclooxygenase-2 (COX-2) ; oxicam family; analgesics;","molecular_formula":"C14H13N3O4S2","molecular_weight":"351.4","state":"solid","clearance":"* 8.8 mL/min [Healthy Male Adults (Fed) oral 7.5 mg tablets]\n* 9.9 mL/min [Eldery Male (Fed) oral 15 mg capsules]\n* 5.1 mL/min [Eldery Female (Fed) oral 15 mg capsules]\n* 19 mL/min [Renal Failure (Fasted) oral 15 mg capsules]\n* 11 mL/min [Hepatic Insufficiency (Fasted) oral 15 mg capsules]","volume_of_distribution":"* 10 L","route_of_elimination":"Meloxicam is almost completely metabolized to four pharmacologically inactive metabolites. Meloxicam excretion is predominantly in the form of metabolites, and occurs to equal extents in the urine and feces. Only traces of the unchanged parent compound are excreted in the urine (0.2%) and feces (1.6%). The extent of the urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.5%, 6% and 13% of the dose were found in urine in the form of meloxicam, and the 5'-hydroxymethyl and 5'-carboxy metabolites, respectively.","protein_binding":"99.4% bound, primarily to albumin","half_life":"15-20 hours","absorption":"Absolute bioavailability = 89%","cid":"54677470","classification":"M","indications":"Acute coronary syndrome; Arthritis; Arthropathy; Cerebrovascular accident; Gastrointestinal disorder; Inflammation; Juvenile idiopathic arthritis; Myocardial infarction; Pain; Rheumatoid arthritis","side_effects":"Abdominal pain; Abdominal pain upper; Accident at home; Anaemia; Angiopathy; Arthralgia; Arthritis; Asthenia; Back pain; Blood urea increased; Bronchitis; Bursitis; Carpal tunnel syndrome; Cataract; Connective tissue disorder; Constipation; Cough; Creatinine renal clearance decreased; Dehydration; Dermatitis; Diarrhoea; Dizziness; Dry mouth; Dyspepsia; Dyspnoea; Ear disorder; Eructation; Eye disorder; Fatigue; Flatulence; Gastritis; Gastrointestinal disorder; Gastrointestinal haemorrhage; Gastrointestinal pain; Gastrooesophageal reflux disease; Gravitational oedema; Haematuria; Headache; Hepatic function abnormal; Hepatobiliary disease; Hyperhidrosis; Hypersensitivity; Hypertension; Immune system disorder; Increased appetite; Infection; Infestation; Influenza; Influenza like illness; Insomnia; Malnutrition; Mediastinal disorder; Melaena; Mental disorder; Mouth ulceration; Muscle spasms; Musculoskeletal discomfort; Myalgia; Nasopharyngitis; Nausea; Nervous system disorder; Oedema; Oedema peripheral; Pain; Pain in extremity; Pharyngitis; Pleuritic pain; Pollakiuria; Pruritus; Purpura; Rash; Rash erythematous; Red blood cell abnormality; Rheumatoid arthritis; Rhinitis; Sinusitis; Skin disorder; Somnolence; Stomatitis; Tinnitus; Upper respiratory tract infection; Urethral disorder; Urinary tract disorder; Urinary tract infection; Vascular purpura; Vertigo; Visual impairment; Vomiting","atc_codes":"M01AC06; M01AC56","group":"Drug","drug_type":"","target":[],"function":["F01","F0105","F0108","F02010102","F02010103","F0206","F0221","F0504","F070105","F070106"],"references":["RC03610","RC02002","RC02623","RC03244","RC04768","RC04781","RC04794","RC04807","RC04820","RC04833","RC04846","RC04859"]},{"compound_ID":"D0080","name":"Metformin","synonyms":"metformin; 657-24-9; 1,1-Dimethylbiguanide; N,N-dimethylimidodicarbonimidic diamide; Metiguanide; Dimethylbiguanide; Glucophage; Haurymelin; Metformine; Fluamine; Flumamine; Gliguanid; Diabex; Melbin; N,N-Dimethylbiguanide; Metformina; Metforminum; Glifage; Glumetza; Islotin; Siofor; N1,N1-Dimethylbiguanide; DMGG; NNDG; Dimethyldiguanide; N,N-Dimethyldiguanide; Metformina [DCIT]; Imidodicarbonimidic diamide, N,N-dimethyl-; Metformina [Spanish]; Metformine [INN-French]; Metforminum [INN-Latin]; Metformin [USAN:INN:BAN]; 1,1-Dimethyl biguanide; LA-6023; BIGUANIDE, 1,1-DIMETHYL-; UNII-9100L32L2N; C4H11N5; EINECS 211-517-8; CHEMBL1431; CHEBI:6801; XZWYZXLIPXDOLR-UHFFFAOYSA-N; 9100L32L2N; Imidodicarbonimidic diamide-, N,N-dimethyl-; 1-carbamimidamido-N,N-dimethylmethanimidamide; Dimethylguanylguanidine; MLS000028493; [14C]metformin; [14C]-metformin; 657M249; Metformin (USAN/INN); NCGC00016564-01; SMR000058277; CAS-1115-70-4; 1-[(diaminomethylidene)amino]-N,N-dimethylmethanimidamide; Dianben; Obimet; Dimethylbiguanid; Metformin base; CCRIS 9321; 3-(diaminomethylidene)-1,1-dimethylguanidine; N-dimethylbiguanide; DMBG; Glucophage (Salt/Mix); n',n'-dimethylbiguanide; Prestwick0_000004; Prestwick1_000004; Prestwick2_000004; Prestwick3_000004; DSSTox_CID_3270; N,N-Dimethylguanylguanidin; SCHEMBL8944; DSSTox_RID_76950; DSSTox_GSID_23270; BSPBio_000007; BSPBio_002314; KBioGR_002310; KBioSS_002312; cid_14219; LA 6023 (Salt/Mix); BIDD:GT0697; SPBio_001928; BPBio1_000009; GTPL4503; GTPL4779; SCHEMBL9913821; DTXSID2023270; SCHEMBL10276396; BDBM57047; CTK2F2882; KBio2_002310; KBio2_004878; KBio2_007446; KBio3_002790; cMAP_000016; HMS2089D19; Tox21_302370; BBL012337; BDBM50229665; HSCI1_000295; STK011633; STL483693; STL484070; ZINC12859773; AKOS000121065; AKOS005206848; AKOS015966566; CCG-102605; DB00331; MCULE-7393156510; 3-carbamimidoyl-1,1-dimethyl-guanidine; NCGC00016564-02; NCGC00016564-03; NCGC00016564-05; NCGC00016564-07; NCGC00188959-01; NCGC00255255-01; AS-65365; CAS-657-24-9; Imidodicarbonimidicdiamide, N,N-dimethyl-; K070; LS-43899; SC-73311; SBI-0206876.P001; AB2000590; CS-0009563; FT-0628266; A19551; C07151; D04966; Q19484; 1-[(E)-amino(dimethylamino)methylidene]guanidine; 15673-EP2269977A2; 15673-EP2269989A1; 15673-EP2270007A1; 15673-EP2270011A1; 15673-EP2272825A2; 15673-EP2272834A1; 15673-EP2272841A1; 15673-EP2275108A1; 15673-EP2275414A1; 15673-EP2280001A1; 15673-EP2287165A2; 15673-EP2287166A2; 15673-EP2292228A1; 15673-EP2292620A2; 15673-EP2295406A1; 15673-EP2295409A1; 15673-EP2295411A1; 15673-EP2295422A2; 15673-EP2298742A1; 15673-EP2298769A1; 15673-EP2298772A1; 15673-EP2298776A1; 15673-EP2298779A1; 15673-EP2301533A1; 15673-EP2301923A1; 15673-EP2301929A1; 15673-EP2301935A1; 15673-EP2301936A1; 15673-EP2305648A1; 15673-EP2305674A1; 15673-EP2308839A1; 15673-EP2308847A1; 15673-EP2308878A2; 15673-EP2314576A1; 15673-EP2314588A1; 15673-EP2316470A2; W-109589; {[amino(dimethylamino)methylidene]amino}methanimidamide; BRD-K79602928-003-04-1; BRD-K79602928-003-08-2; 3-(diaminomethylene)-1,1-dimethyl-guanidine;hydrochloride; 3-(diaminomethylidene)-1,1-dimethylguanidine;hydrochloride; 3-[bis(azanyl)methylidene]-1,1-dimethyl-guanidine;hydrochloride; MF8","trade_name":"Fortamet, Glucophage, Glumetza","abbrev_name":"","description":"Antidiabetics; biguanide antihyperglycemic agent; insulin sensitizer","molecular_formula":"C4H11N5","molecular_weight":"129.16","state":"solid","clearance":"Renal clearance is about 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours [FDA label].","volume_of_distribution":"The apparent volume of distribution (V/F) of metformin after one oral dose of metformin 850 mg averaged at 654 ± 358 L [FDA label].","route_of_elimination":"This drug is substantially excreted by the kidney [FDA label]. \n\nRenal clearance of metformin is about 3.5 times higher than creatinine clearance, which shows that renal tubular secretion is the major route of metformin elimination. After oral administration, about 90% of absorbed metformin is eliminated by the kidneys within the first 24 hours post-ingestion [FDA label].","protein_binding":"Metformin is negligibly bound to plasma proteins [FDA label], in contrast to sulfonylureas, which are more than 90% protein bound [A176140].","half_life":"Approximately 6.2 hours in the plasma [FDA label] and in the blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution [FDA label].","absorption":"\n**Regular tablet absorption**\n\nThe absolute bioavailability of a metformin 500 mg tablet administered in the fasting state is about 50%-60%. Single-dose clinical studies using oral doses of metformin 500 to 1500 mg and 850 to 2550 mg show that there is a lack of dose proportionality with an increase in metformin dose, attributed to decreased absorption rather than changes in elimination [FDA label]. \n\nAt usual clinical doses and dosing schedules of metformin, steady-state plasma concentrations of metformin are achieved within 24-48 hours and are normally measured at <1 μg/mL [FDA label].\n\n**Extended-release tablet absorption**\n\nAfter a single oral dose of metformin extended-release, Cmax is reached with a median value of 7 hours and a range of between 4 and 8 hours. Peak plasma levels are measured to be about 20% lower compared to the same dose of regular metformin, however, the extent of absorption of both forms (as measured by area under the curve - AUC), are similar [FDA label].\n\n**Effect of food**\n\nFood reduces the absorption of metformin, as demonstrated by about a 40% lower mean peak plasma concentration (Cmax), a 25% lower area under the plasma concentration versus time curve (AUC), and a 35-minute increase in time to peak plasma concentration (Tmax) after ingestion of an 850 mg tablet of metformin taken with food, compared to the same dose administered during fasting [FDA label].\n\nThough the extent of metformin absorption (measured by the area under the curve - AUC) from the metformin extended-release tablet is increased by about 50% when given with food, no effect of food on Cmax and Tmax of metformin is observed. High and low-fat meals exert similar effects on the pharmacokinetics of extended-release metformin [FDA label].","cid":"4091","classification":"A","indications":"Acute coronary syndrome; Blood glucose decreased; Coma; Diabetic ketoacidosis; Fasting; Hyperglycaemia; Hypersensitivity; Ketosis; Lactic acidosis; Metabolic acidosis; Myocardial infarction; Obesity; Type 1 diabetes mellitus; Type 2 diabetes mellitus; Weight decreased","side_effects":"Abdominal discomfort; Abdominal distension; Abdominal pain; Asthenia; Constipation; Diarrhoea; Dysgeusia; Dyspepsia; Flatulence; Gastrointestinal disorder; Gastrointestinal pain; Headache; Hypoglycaemia; Infection; Injury; Nausea; Rhinitis; Vomiting","atc_codes":"A10BD05; A10BD13; A10BD07; A10BD11; A10BD15; A10BD14; A10BD22; A10BD23; A10BA02; A10BD20; A10BD18; A10BD02; A10BD03; A10BD08; A10BD16; A10BD17; A10BD25; A10BD10","group":"Drug","drug_type":"","target":["T001","T002","T004","T005","T019","T020","T077","T106","T107","T108","T109","T387","T400","T408"],"function":["F0108","F0201","F02010102","F02010103","F02010104","F02010202","F02010204","F020103","F020104","F020201","F020202","F020301","F020302","F020303","F020304","F02040101","F02040102","F02040103","F021201","F0303","F05"],"references":["RC00157","RC00158","RC00159","RC00160","RC00161","RC00622","RC00623","RC00624","RC00625","RC00626","RC00627","RC00628","RC00629","RC00630","RC00631","RC00632","RC00633","RC00634","RC00635","RC00636","RC00637","RC00638","RC00639","RC00640","RC00641","RC00642","RC00643","RC00644","RC00645","RC00646","RC00647","RC00648","RC00649","RC00650","RC00651","RC00652","RC00653","RC00654","RC00655","RC00656","RC00657","RC00658","RC00659","RC00666","RC00667","RC00668","RC00669","RC00670","RC00671","RC00672","RC00673","RC00674","RC00675","RC00676","RC00677","RC00678","RC00679","RC00680","RC00681","RC00682","RC00683","RC00684","RC00685","RC00686","RC00687","RC00758","RC00759","RC00764","RC00767","RC00770","RC00773","RC00777","RC00781","RC00784","RC00787","RC00790","RC00793","RC00796","RC00797","RC00798","RC00801","RC00802","RC00803","RC00806","RC00807","RC00808","RC00936","RC03629","RC04087","RC04211","RC04335","RC04459","RC04583"]},{"compound_ID":"D0081","name":"Metamfetamine","synonyms":"METHAMPHETAMINE; Metamfetamine; d-Methamphetamine; d-Deoxyephedrine; d-Desoxyephedrine; d-N-Methylamphetamine; Metamphetamine; d-Methylamphetamine; Methylamphetamine; d-Phenylisopropylmethylamine; N-Methylamphetamine; (S)-Methamphetamine; Norodin; (+)-Methylamphetamine; d-(S)-Methamphetamine; D-1-Phenyl-2-methylaminopropane; Metamfetaminum; Desyphed; (+)-N-Methylamphetamine; (S)-Methylamphetamine; (+)-(S)-Deoxyephedrine; Methyl-beta-phenylisopropylamine; 1-Phenyl-2-methylaminopropane; (S)-(+)-Deoxyephedrine; Metamfetamina; Metanfetamina; Stimulex; Speed; (+)-methamphetamine; 537-46-2; S-(+)-Methamphetamine; (S)-N,alpha-Dimethylbenzeneethanamine; Methamphetaminum; (2S)-N-methyl-1-phenylpropan-2-amine; D-N,alpha-dimethylphenethylamine; Metamfetaminum [INN-Latin]; Metamfetamina [INN-Spanish]; Metanfetamina [INN-Spanish]; Methamphetaminum [INN-Latin]; (+)-2-(N-Methylamino)-1-phenylpropane; Meth; Metamfetamine [INN]; N-Methyl-beta-phenylisopropylamine; Methamphetaminum [JP]; 1-Phenyl-2-methylamino-propan [German]; Metamfetaminum [Latin]; (+)-N,alpha-Dimethylphenethylamine; d-1-Phenyl-2-methylaminopropan [German]; Metanfetamina [Spanish]; (+)-N,alpha-Dimethyl-beta-phenylethylamine; D-1-Phenyl-2-methylaminopropan; 2S-(+)-Methamphetamine; (S)-(+)-Methamphetamine; (+)-(S)-N-alpha-Dimethylphenethylamine; N-Methyl-beta-phenylisopropylamin [German]; NSC 25115; dextromethamphetamine; (S)-N,alpha-Dimethylbenzeneethanoamine; UNII-44RAL3456C; CHEBI:6809; (S)-(+)-N,alpha,dimethylphenethylamine; Metamfetamine (INN); (alphaS)-N,alpha-dimethylbenzeneethanamine; HSDB 3359; Benzeneethanamine, N,alpha-dimethyl-, (S)-; Methyl-.beta.-phenylisopropylamine; d-N,.alpha.-Dimethylphenethylamine; Methamphetamine hydrochloride; EINECS 208-668-7; Phenethylamine, N,alpha-dimethyl-, (+)-; DEA No. 1105; Benzeneethanamine, N,alpha-dimethyl-, (+)-; MYWUZJCMWCOHBA-VIFPVBQESA-N; 44RAL3456C; Benzeneethanamine, N,alpha-dimethyl-, (alphaS)-; 1-Phenyl-2-methylamino-propan; N-Methyl-beta-phenylisopropylamin; Crank; Methamphetamine, its salts, isomers, and salts of its isomers; Crystal Meth; Phenethylamine, N,alpha-dimethyl-, (S)-(+)-; Meth (Street Name); ICE [Street Name]; Crank [Street Name]; Speed [Street Name]; Crystal Meth [Street Name]; N-Methyl-1-phenyl-2-propanamine; (+ )-Methylamphetamine; C10H15N; B40; Benzeneethanamine, N,.alpha.-dimethyl-, (S)-; Phenethylamine, N,.alpha.-dimethyl-, (S)-(+)-; Epitope ID:178090; intra-venous methamphetamine; Benzeneethanamine,.alpha.-dimethyl-, (S)-; d-N,a-dimethylphenethylamine; SCHEMBL42615; Phenethylamine,.alpha.-dimethyl-, (S)-(+)-; CHEMBL1201201; DTXSID8037128; WLN: 1MY1&1R -D; Desyphed hydrochloride (Salt/Mix); NSC25115; ZINC6021043; N-Methyl-1-phenyl-2-propanamine #; BDBM50359499; NSC-25115; PDSP1_001404; PDSP1_001405; PDSP2_001388; PDSP2_001389; (+)-N,.alpha.-Dimethylphenethylamine; (S)-N-methyl-1-phenylpropan-2-amine; DB01577; Desoxyephedrine hydrochloride (Salt/Mix); methyl[(2S)-1-phenylpropan-2-yl]amine; Phenethylamine,.alpha.-dimethyl-, (+)-; (+)-(S)-N-.alpha.-Dimethylphenethylamine; Benzeneethanamine,.alpha.-dimethyl-, (+)-; LS-103331; Phenethylamine, N,.alpha.-dimethyl-, (+)-; Benzeneethanamine, N,.alpha.-dimethyl-, (+)-; C07164; D08187; (+)-N,.alpha.-Dimethyl-.beta.-phenylethylamine; Q191924; Phenethylamine, N,alpha-dimethyl-, (S)-(+)- (8CI); Benzeneethanamine, N,alpha-dimethyl-, (alphaS)- (9CI); UNII-13ZT6YG5SD component MYWUZJCMWCOHBA-VIFPVBQESA-N; (+)-N,.alpha.-Dimethylphenethylamine hydrochloride (Salt/Mix); 139-47-9; S(+)-Methamphetamine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material","trade_name":"Desoxyn, Methedrine","abbrev_name":"Meth","description":"a potent central nervous system (CNS) stimulant","molecular_formula":"C10H15N","molecular_weight":"149.23","state":"solid","clearance":"","volume_of_distribution":"","route_of_elimination":"Excretion occurs primarily in the urine, the rate of which is dependent on urine pH. Between 30-54% of an oral dose is excreted in urine as unchanged methamphetamine and 10-23% as unchanged amphetamine. Following an intravenous dose, 45% is excreted as unchanged parent drug and 7% amphetamine.","protein_binding":"","half_life":"The biological half-life has been reported in the range of 4 to 5 hours.","absorption":"Methamphetamine is rapidly absorbed from the gastrointestinal tract with peak methamphetamine concentrations occurring in 3.13 to 6.3 hours post ingestion. Moreover, when administered intranasally or as an inhalation, methamphetamine also demonstrates a high degree of absorption. It is distributed to most parts of the body. Because methamphetamine has a high lipophilicity it is distributed across the blood brain barrier and crosses the placenta.","cid":"10836","classification":"N","indications":"Affect lability; Agitation; Attention deficit/hyperactivity disorder; Distractibility; Electroencephalogram abnormal; Hyperkinesia; Learning disability; Mood swings; Obesity","side_effects":"","atc_codes":"N06BA03","group":"Drug","drug_type":"","target":[],"function":["F0308"],"references":["RC03704"]},{"compound_ID":"D0082","name":"Methotrexate","synonyms":"methotrexate; 59-05-2; Amethopterin; Rheumatrex; Trexall; Metatrexan; Hdmtx; Abitrexate; Methylaminopterinum; Methotrexatum; Metotrexato; Methylaminopterin; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; 4-Amino-10-methylfolic acid; Methotrexate hydrate; Methotrexat; Maxtrex; Rasuvo; A-Methopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; N-Bismethylpteroylglutamic acid; Methotrexate, L-; Methoxtrexate; NCI-C04671; Antifolan; Metotressato [DCIT]; Mexate-Aq; NSC-740; CL-14377; UNII-YL5FZ2Y5U1; 133073-73-1; Methotrexatum [INN-Latin]; Metotrexato [INN-Spanish]; Amethopterine; Emtexate; EMT 25,299; L-Amethopterin; CCRIS 1109; 4-Aminomethylpteroylglutamic acid; HSDB 3123; NSC 740; TCMDC-125858; (+)-4-Amino-10-methylfolic acid; Abitrexate (Methotrexate); EINECS 200-413-8; R 9985; YL5FZ2Y5U1; Methotextrate; CHEMBL34259; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid; AI3-25299; NSC740; X 133; 4-Amino-N(sup 10)-methylpteroylglutamic acid; CHEBI:44185; N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid; (2S)-2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioic acid; N-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)carbonyl]-L-glutamic acid; CL14377; Kyselina 4-amino-N(sup 10)-methylpteroylglutamova [Czech]; NCGC00025060-04; C20H22N8O5; CL 14377; 4-amino-N(10)-methylpteroylglutamic acid; DSSTox_CID_822; N-(p-(((2,4-Diamino-6-pteridyl)methyl)methylamino)benzoyl)glutamic acid; N-(4-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)-L-glutamicacid; DSSTox_RID_75810; Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)methylamino)benzoyl)-L-glutamova [Czech]; L-(+)-N-(p-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)glutamic acid; N-(p-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)-L-(+)-glutamic acid; DSSTox_GSID_20822; Fauldexato; Medsatrexate; Methoblastin; Metotressato; Brimexate; Emthexat; Emthexate; Lantarel; Lumexon; Metrotex; Novatrex; Otrexup; Tremetex; Trexeron; Trixilem; Metex; Texate; MLS001401431; (4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzoyl)-L-glutamic acid; [3H]methotrexate; Glutamic acid, N-(p-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-, L-; SMR000112001; [3H]-methotrexate; SR-01000075682; SMR000449324; FBOZXECLQNJBKD-UHFFFAOYSA-N; Metolate; Nordimet; Xatmep; Antifolan hydrate; Intradose-MTX; MTX hydrate; 1dhi; 1dhj; 2drc; 4ocx; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]pentanedioic acid; N-(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)-L-glutamic acid; N-{4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl}-L-glutamic acid; CAS-59-05-2; Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)methylamino)benzoyl)-L-glutamova; MPI-2505; Prestwick_322; Methotrexate [USAN:INN:BAN:JAN]; Otrexup (TN); MFCD00150847; Xatmep (TN); folic acid antagonist; An-PDN; Methylaminopterin; MTX; DL-Amethopterin hydrate; Intrathecal methotrexate; Methotrexate [USAN:USP:INN:BAN:JAN]; Spectrum_001836; Tocris-1230; 4kn0; WR-19039; Methylaminopterin hydrate; Prestwick0_000135; Prestwick1_000135; Prestwick2_000135; Spectrum2_001077; Spectrum3_000497; Spectrum4_000616; Spectrum5_000958; Methotrexate - Abitrexate; L(+)-Amethopterin hydrate; NCIMech_000767; SCHEMBL3711; BIDD:PXR0175; Lopac0_000020; KBioGR_001172; KBioSS_002341; KSC269O8T; Kyselina 4-amino-N(sup 10)-methylpteroylglutamova; MLS000049968; MLS002154208; DivK1c_000114; SPBio_001094; SPBio_002149; cid_126941; cid_165528; GTPL4674; GTPL4815; DTXSID4020822; SCHEMBL12421860; BDBM18050; BDBM66082; CTK1G9789; HMS500F16; KBio1_000114; KBio2_002338; KBio2_004906; KBio2_007474; KBio3_001493; Methotrexate (JP17/USP/INN); AOB5585; FBOZXECLQNJBKD-ZDUSSCGKSA-N; g301; NINDS_000114; Bio1_000486; Bio1_000975; Bio1_001464; HMS1568K12; HMS2095K12; HMS2233O18; HMS3260C21; HMS3414L09; HMS3678L07; HMS3712K12; ACT03341; APC-2002; BCP13701; KS-00000L8X; MPI-5004; ZINC1529323; Tox21_110944; Tox21_300269; Tox21_500020; 4-Amino-10-methylfolic acid hydrate; ANW-72813; CCG-35800; LS-249; s1210; STL535338; AKOS016340329; Tox21_110944_1; AB02593; ACN-050905; CS-1732; DB00563; KS-5093; LP00020; MCULE-6523054194; RTR-020497; IDI1_000114; SMP2_000020; (methyl)amino)benzamido)pentanedioic acid; NCGC00025060-01; NCGC00025060-02; NCGC00025060-03; NCGC00025060-05; NCGC00025060-06; NCGC00025060-07; NCGC00025060-08; NCGC00025060-09; NCGC00025060-10; NCGC00025060-11; NCGC00025060-12; NCGC00025060-13; NCGC00025060-15; NCGC00025060-16; NCGC00254216-01; NCGC00260705-01; BR-77824; HY-14519; SC-19293; EU-0100020; FT-0082628; FT-0601523; G-301; SW198601-3; Methotrexate 1.0 mg/ml in Dimethyl Sulfoxide; 1771-EP0930075A1; 1771-EP2269989A1; 1771-EP2269994A1; 1771-EP2270001A1; 1771-EP2270008A1; 1771-EP2270018A1; 1771-EP2270505A1; 1771-EP2272825A2; 1771-EP2272827A1; 1771-EP2272832A1; 1771-EP2275413A1; 1771-EP2275420A1; 1771-EP2277565A2; 1771-EP2277566A2; 1771-EP2277567A1; 1771-EP2277568A2; 1771-EP2277569A2; 1771-EP2277570A2; 1771-EP2277865A1; 1771-EP2277876A1; 1771-EP2280012A2; 1771-EP2281563A1; 1771-EP2281815A1; 1771-EP2287156A1; 1771-EP2289892A1; 1771-EP2289894A2; 1771-EP2292233A2; 1771-EP2292280A1; 1771-EP2292595A1; 1771-EP2292614A1; 1771-EP2292615A1; 1771-EP2292617A1; 1771-EP2295055A2; 1771-EP2295416A2; 1771-EP2295426A1; 1771-EP2295427A1; 1771-EP2298743A1; 1771-EP2298748A2; 1771-EP2298764A1; 1771-EP2298765A1; 1771-EP2298768A1; 1771-EP2298772A1; 1771-EP2298778A1; 1771-EP2298780A1; 1771-EP2301928A1; 1771-EP2301933A1; 1771-EP2305243A1; 1771-EP2305640A2; 1771-EP2305642A2; 1771-EP2305660A1; 1771-EP2305668A1; 1771-EP2305671A1; 1771-EP2305679A1; 1771-EP2305689A1; 1771-EP2308833A2; 1771-EP2308839A1; 1771-EP2308855A1; 1771-EP2308861A1; 1771-EP2311453A1; 1771-EP2311807A1; 1771-EP2311808A1; 1771-EP2311825A1; 1771-EP2311827A1; 1771-EP2311829A1; 1771-EP2311840A1; 1771-EP2311842A2; 1771-EP2311850A1; 1771-EP2314590A1; 1771-EP2316459A1; 1771-EP2316832A1; 1771-EP2316833A1; 1771-EP2316834A1; 1771-EP2371811A2; 1771-EP2374454A1; 5947-EP0930075A1; 5947-EP2269994A1; 5947-EP2289892A1; 73M731; A-2190; A10021; C01937; D00142; J10045; DL-4-Amino-N10-methylpteroylglutamic acid hydrate; Q422232; SR-01000597411; W-60383; (S)-2-(4-(((2,4-diaminopteridin-6-yl)methyl); Q-201366; SR-01000075682-1; SR-01000075682-2; SR-01000075682-6; SR-01000597411-1; W-105347; 2,2'-(9,10-anthracenediylidene)-bis-propanedinitrile; BRD-K59456551-001-09-3; BRD-K59456551-001-11-9; WLN: T66 BN DN GN JNJ CZ EZ H1N1&R DVMYVQ2VQ; Z1541638527; UNII-99ITO15X8S component FBOZXECLQNJBKD-ZDUSSCGKSA-N; Methotrexate, European Pharmacopoeia (EP) Reference Standard; Methotrexate, United States Pharmacopeia (USP) Reference Standard; Glutamic acid,4-diamino-6-pteridinyl)methyl] methylamino]benzoyl]-, L-(+)-; L-Glutamic acid,4-diamino-6-pteridinyl)methyl]- methylamino]benzoyl]-; L-Glutamic acid,N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-,hydrate(9ci); L-Glutamicacid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-; Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard; Methotrexate for system suitability, European Pharmacopoeia (EP) Reference Standard; Methotrexate, Pharmaceutical Secondary Standard; Certified Reference Material; N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino]benzoyl]-L-glutamic acid; (2S)-2-[[[4-[(2,4-diamino-6-pteridinyl)methyl-methylamino]phenyl]-oxomethyl]amino]pentanedioic acid;hydrate; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]glutaric acid;hydrate; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid;hydrate; (2S)-2-[[4-[[2,4-bis(azanyl)pteridin-6-yl]methyl-methyl-amino]phenyl]carbonylamino]pentanedioic acid;hydrate; 70359-39-6; L-Glutamic acid,N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-, hydrate (9CI); Methotrexate, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production, meets EP, USP testing specifications","trade_name":"Trexall, Rheumatrex, Otrexup","abbrev_name":"MTX, amethopterin","description":"chemotherapy agent and immune system suppressant","molecular_formula":"C20H22N8O5","molecular_weight":"454.4","state":"solid","clearance":"Methotrexate clearance rates vary widely and are generally decreased at higher doses. Delayed drug clearance has been identified as one of the major factors responsible for methotrexate toxicity.","volume_of_distribution":"* 0.18 L/kg [initial volume of distribution (Vd)]\n* 0.4 - 0.8 L/kg [steady state Vd] \nMethotrexate competes with reduced folates for active transport across cell membranes by means of a single carrier-mediated active transport process. At serum concentrations greater than 100 micromolar, passive diffusion becomes a major pathway by which effective intracellular concentrations can be achieved. Methotrexate does not cross the blood-brain-barrier.","route_of_elimination":"Renal excretion is the primary route of elimination and is dependent upon dosage and route of administration. IV administration, 80% to 90% of the administered dose is excreted unchanged in the urine within 24 hours. There is limited biliary excretion amounting to 10% or less of the administered dose.","protein_binding":"50% bound to protein, primarily to albumin","half_life":"Low doses (less than 30 mg/m^2): 3 to 10 hours; High doses: 8 to 15 hours.","absorption":"Oral absorption is dose dependent in adults and leukemic pediatric patients. In adults, peak serum levels are reached within one to two hours. At doses of 30 mg/m^2 or less, methotrexate is generally well absorbed with a mean bioavailability of 60%. At doses greater than 80 mg/m^2, the absorption of the doses is significantly less due to a saturation effect.","cid":"126941","classification":"L","indications":"Acute leukaemia; Acute lymphocytic leukaemia; Benign hydatidiform mole; Bladder cancer; Breast cancer; Bronchial carcinoma; Burkitt's lymphoma; Choriocarcinoma; Drug interaction; Fungal infection; Hodgkin's disease; Hodgkin's disease lymphocyte depletion type stage unspecified; Hodgkin's disease lymphocyte predominance type stage unspecified; Juvenile idiopathic arthritis; Leukaemia; Leukaemic infiltration brain; Lung neoplasm malignant; Lymphocytic leukaemia; Lymphoma; Malignant hydatidiform mole; Metastasis; Metastatic neoplasm; Neoplasm; Neoplasm malignant; Oesophageal carcinoma; Osteosarcoma; Osteosarcoma metastatic; Psoriatic arthropathy; Rheumatoid arthritis; Squamous cell carcinoma; Testis cancer","side_effects":"","atc_codes":"L01BA01; L04AX03","group":"Drug","drug_type":"","target":[],"function":["F02060101"],"references":["RC03555"]},{"compound_ID":"D0083","name":"Mitomycin","synonyms":"mitomycin C; Mitomycin; 50-07-7; Ametycine; Mutamycin; Mitocin-C; Mitomycin-C; Ametycin; Mitomycinum; Mytomycin; Mytozytrex; Mitozytrex; Mitomycinum C; Mitocin C; Mitomycins; Mitamycin; MMC; Mitosol; 7-Amino-9alpha-methoxymitosane; NSC-26980; Mitomycyna C [Polish]; Mito-C; Mit-C; Mitomycine [INN-French]; Mitomycinum [INN-Latin]; Mitomicina [INN-Spanish]; NSC 26980; Mitomycyna C; C15H18N4O5; NCI-C04706; RCRA waste number U010; NSC26980; Mitomycine; CCRIS 414; UNII-50SG953SK6; HSDB 3239; EINECS 200-008-6; RCRA waste no. U010; AI3-26199; CHEBI:27504; 50SG953SK6; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS-(1aalpha,8beta,8aalpha,8balpha))-; Mitomicina; DSSTox_CID_898; DSSTox_RID_75853; DSSTox_GSID_20898; Mitomycin (TN); 6-Amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methylazirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione carbamate (ester); Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS,8S,8aR,8bS)-; CAS-50-07-7; Muamycin (TN); ((1aS,8S,8aR,8bS)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2',3':3,4]pyrrolo[1,2-a]indol-8-yl)methyl carbamate; [(1aS,8S,8aR,8bS)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate; [1aS-(1a?,8?,8a?,8b?)]-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methyl-, carbamate (ester); Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS,8S,8aR,8bS)-; Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, [1aS-(1aalpha,8beta,8aalpha,8balpha)]-; Mitomycin [USAN:INN:BAN]; Mitomycin (USP/INN); 1404-00-8; MLS002702984; (amino-methoxy-methyl-dioxo-[?]yl)methyl carbamate; Mitomycin C, Streptomyces caespitosus; 7-Amino-9.alpha.-methoxymitosane; Mitonco; Mitoplus; MitoExtra; Mitomycin [USAN:USP:INN:BAN]; NCGC00095258-01; [(1aS,8S,8aR,8bS)-6-Amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2'',3'':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate; [(1aS,8S,8aR,8bS)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate; Mitomycin C, Streptomyces caespitosus, Carrier-Free; Mitomycin C from Streptomyces caespitosus; Mitomycin C (JP17); CHEMBL105; SCHEMBL3760; CBiol_001927; BSPBio_001267; KBioGR_000607; KBioSS_000607; MLS001332654; Mitozytrex (TN) (Supergene); AMETYCIN pound notmitomycin C; GTPL7089; DTXSID2020898; KBio2_000607; KBio2_003175; KBio2_005743; KBio3_001073; KBio3_001074; EX-A501; NWIBSHFKIJFRCO-WUDYKRTCSA-N; ZX-AFC000411; BCPP000410; Bio1_000213; Bio1_000702; Bio1_001191; Bio2_000464; Bio2_000944; HMS1362O09; HMS1792O09; HMS1990O09; HMS2089F16; HMS3403O09; Tox21_111493; BDBM50428658; GR-311; LS-136; MFCD00078109; s8146; ZINC30726187; AKOS015895703; Tox21_111493_1; ACN-038344; BCP9000285; CCG-208564; CS-0564; DB00305; KS-5148; IDI1_002219; SMP1_000307; NCGC00163468-02; NCGC00163468-03; NCGC00163468-05; NCGC00163468-06; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS-(1aalpha,8beta,8aalpha,8balpha))- (9CI); CC-30970; HY-13316; SC-17000; SMR000058401; BCP0726000181; LS-173087; M2320; C06681; D00208; W-5071; AB00918689-03; AB00918689-04; 078M109; C-20147; Mitomycin C, Antibiotic for Culture Media Use Only; Q-201410; BRD-K59670716-001-02-6; BRD-K59670716-001-06-7; Q19856779; Mitomycin C, contains 2 mg Mitomycin C and 48 mg NaCl; UNII-V03E10691T component NWIBSHFKIJFRCO-WUDYKRTCSA-N; WLN: T D3 B556 BN EM JV MVTTT&J GO1 H1OVZ KZ L1; Mitomycin C from Streptomyces caespitosus, >=970 mug/mg (USP XXIV); Mitomycin C from Streptomyces caespitosus, powder, BioReagent, suitable for cell culture; Mitomycin C from Streptomyces caespitosus, powder, contains NaCl as solubilizer; (1ar)-6-amino-8-(((aminoc arbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione; (1ar)-6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione; [(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.0^{2,7}.0^{4,6}]trideca-1(9),11-dien-8-yl]methyl carbamate; [1aR-(1aalpha,8beta,8aalpha,8balpha)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-alpha]indole-4,7-dione; [1aS-(1aalpha,8beta,8aalpha,8balpha)]-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione; 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methylazirino[2',3':3, 4]pyrrolo[1,2-a]indole-4,7-dione, carbamate (ester); 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, carbamate (ester); 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl, [1aS-(1aalpha,8beta,8aalpha,8balpha)]-azirino[2',3':3,4]pyrrol o[1,2a]indole-4,7-dione; 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl, [1aS-(1aalpha,8beta,8aalpha,8balpha)]-azirino[2',3':3,4]pyrrolo[1,2a]indole-4,7-dione; Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl -, [1aS-(1aalpha,8beta,8aalpha,8balpha)]-; Azirino[2',4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a- methoxy-5-methyl-, carbamate (ester); Azirino[2',4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b- hexahydro-8a-methoxy-5-methyl-, [1aR-(1a.alpha.,8.beta.,8a.alpha.,8b.alpha.)]-; Mitomycin C from Streptomyces caespitosus, >=98% (HPLC), potency: >=970 mug per mg (USP XXIV), gamma-irradiated, suitable for cell culture","trade_name":"","abbrev_name":"","description":"","molecular_formula":"C15H18N4O5","molecular_weight":"334.33","state":"solid","clearance":"","volume_of_distribution":"","route_of_elimination":"Approximately 10% of a dose of mitomycin is excreted unchanged in the urine.","protein_binding":"","half_life":"8-48 min","absorption":"Erratic.","cid":"5746","classification":"L","indications":"Metastatic neoplasm; Neoplasm malignant","side_effects":"Pulmonary oedema (0.65)","atc_codes":"L01DC03","group":"Drug","drug_type":"","target":["T001","T002","T408"],"function":["F0108","F0201","F0303"],"references":["RC04091","RC04215","RC04339","RC04463","RC04587"]},{"compound_ID":"D0084","name":"Mitoxantrone","synonyms":"mitoxantrone; 65271-80-9; Mitozantrone; Mitoxanthrone; DHAQ; Dihydroxyanthraquinone; Mitoxantron; Novantrone; Mitoxantrona; Mitoxantronum; Mitoxantronum [INN-Latin]; Mitoxantrona [INN-Spanish]; Mitoxantrone [INN]; NSC 279836; UNII-BZ114NVM5P; DHAD; NSC279836; Mitoxantrone (INN); CCRIS 7604; C22H28N4O6; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; NSC-279836; BRN 2795126; BZ114NVM5P; 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; MLS002703044; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; CHEBI:50729; KKZJGLLVHKMTCM-UHFFFAOYSA-N; NSC299195; NSC301739; NSC-299195; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-; ANTHRAQUINONE, 5,8-BIS((2-((2-HYDROXYETHYL)AMINO)ETHYL)AMINO)-1,4-DIHYDROXY-; MIX; MLS001333711; Misostol (TN); 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione; NCGC00015693-02; Mitoxantrone (free base); SMR000058480; Mitoxantrone [INN:BAN]; CAS-70476-82-3; DHAQ (*Diacetate salt*); SR-01000076001; 2fum; 1,4-dihydroxy-5,8-bis(2-(2-hydroxyethylamino)ethylamino)anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthracene-9,10-dione; NSC-301739D; Immunex (Salt/Mix); NSC-287836; Spectrum_001655; Liposome Encapsulated Mitoxantrone (LEM); CHEMBL58; Prestwick0_000385; Prestwick1_000385; Prestwick2_000385; Prestwick3_000385; Spectrum2_000908; Spectrum3_001590; Spectrum4_000866; Spectrum5_001205; Lopac-M-6545; cid_4212; Neuro_000153; SCHEMBL3000; BIDD:PXR0181; Lopac0_000779; BSPBio_000569; BSPBio_003160; KBioGR_001531; KBioSS_002135; AN-584/42007670; DivK1c_000516; SPBio_000756; SPBio_002490; BPBio1_000627; GTPL7242; Novantrone(R) (mitoxantrone for injection concentrate); DTXSID4046947; BDBM67690; cid_5458171; CTK8A5416; KBio1_000516; KBio2_002135; KBio2_004703; KBio2_007271; KBio3_002660; NINDS_000516; HMS2090D05; HMS3655E20; KUC108634N; BCP02861; EBD32557; ZINC3794794; CCG-36371; CM0184; s1889; STK631833; Mitoxantrone hydrochloride (Salt/Mix); AKOS005564036; API0003408; BCP9000931; CS-2524; DB01204; KSC-19-204; MCULE-5513787065; IDI1_000516; SMP2_000179; NCGC00015693-01; NCGC00015693-03; NCGC00015693-04; NCGC00015693-05; NCGC00015693-06; NCGC00015693-08; NCGC00162251-01; AK323601; AS-35321; HY-13502; K061; LS-20638; MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; NCI60_002276; NCI60_002535; SC-22733; SMR001549953; SY226320; SBI-0050757.P003; TX-017756; AB00053716; FT-0630752; SW196745-6; MFCD00242942 (95%); VU0244399-2; 71M809; C11195; D08224; 13181-EP2270008A1; 13181-EP2270505A1; 13181-EP2272827A1; 13181-EP2275420A1; 13181-EP2277876A1; 13181-EP2289892A1; 13181-EP2292617A1; 13181-EP2295055A2; 13181-EP2295412A1; 13181-EP2295413A1; 13181-EP2295416A2; 13181-EP2295426A1; 13181-EP2295427A1; 13181-EP2298748A2; 13181-EP2298764A1; 13181-EP2298765A1; 13181-EP2301928A1; 13181-EP2305642A2; 13181-EP2305660A1; 13181-EP2311453A1; 13181-EP2311808A1; 13181-EP2311829A1; 13181-EP2311837A1; 13181-EP2311840A1; 13181-EP2311842A2; 13181-EP2316832A1; 13181-EP2316833A1; 13181-EP2316834A1; AB00053716-18; AB00053716-19; AB00053716-22; AB00053716_23; AB00053716_24; Q239426; SR-01000076001-7; BRD-K21680192-001-01-5; BRD-K21680192-001-11-4; BRD-K21680192-300-05-2; BRD-K21680192-300-07-8; BRD-K21680192-300-09-4; BRD-K21680192-300-10-2; BRD-K21680192-300-12-8; 1,4-bis[2-(2-hydroxyethylamino)-ethylamino]-5,8-dihydroxyanthraquinone; 1,4-bis[2-(2-hydroxyethylamino)ethylamino]-5,8-dihydroxyanthraquinone; 1,4-dihydroxy-5,8-bis[[2-(2-hydroxyethylamino)ethyl]amino]anthraquinone; 9, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl] amino]-; 1,4-Bis[[2-[(2-hydroxyethyl)amino]ethyl]imino]-1,4-dihydroanthracene-5,8,9,10-tetrol; 1,4-Dihydroxy-5,8-bis-[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthraquinone; 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]-9,10-anthraquinone;hydrochloride; 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]-anthracene-9,10-dione; 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione;hydrochloride; 1,4-bis[2-(2-hydroxyethylamino)ethylamino]-5,8-bis(oxidanyl)anthracene-9,10-dione;hydrochloride; 1,4-dihydroxy-5,8-bis[2-[(1,1,2,2-tetradeuterio-2-hydroxyethyl)amino]ethylamino]anthracene-9,10-dione; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9CI); Mitozantrone|||Novantron|||CL-232325|||1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione","trade_name":"","abbrev_name":"","description":"","molecular_formula":"C22H28N4O6","molecular_weight":"444.5","state":"liquid","clearance":"* 21.3 L/hr/m2 [Elderly patients with breast cancer receiving IV administration of 15-90 mg/m2]\n* 28.3 L/hr/m2 [Non-elderly patients with nasopharyngeal carcinoma receiving IV administration of 15-90 mg/m2]\n* 16.2 L/hr/m2 [Non-elderly patients with malignant lymphoma receiving IV administration of 15-90 mg/m2]","volume_of_distribution":"* 1000 L/m2","route_of_elimination":"","protein_binding":"0.78","half_life":"75 hours","absorption":"Poorly absorbed following oral administration","cid":"4212","classification":"L","indications":"Acute lymphocytic leukaemia; Acute myeloid leukaemia; Blast cell crisis; Chronic myeloid leukaemia; Disability; Hepatic cancer; Hepatic function abnormal; Hepatocellular carcinoma; Hormone-refractory prostate cancer; Leukaemia; Liver disorder; Lymphocytic leukaemia; Lymphoma; Metastatic neoplasm; Multiple sclerosis; Neoplasm malignant; Pain; Prostate cancer; Relapsing-remitting multiple sclerosis","side_effects":"Anxiety (0.05); Vision blurred (0.03); Abdominal pain; Abdominal pain upper; Agranulocytosis; Alanine aminotransferase increased; Alopecia; Amenorrhoea; Anaemia; Arrhythmia; Aspartate aminotransferase increased; Asthenia; Back pain; Blood glucose increased; Blood potassium decreased; Body temperature increased; Conjunctivitis; Constipation; Convulsion; Cough; Diarrhoea; Dyspnoea; Ecchymosis; Electrocardiogram abnormal; Foot and mouth disease; Fungal infection; Fungal skin infection; Gamma-glutamyltransferase increased; Gastrointestinal pain; Haemoglobin; Haemoglobin decreased; Haemorrhage; Headache; Infection; Jaundice; Leukopenia; Menorrhagia; Menstrual disorder; Mucosal inflammation; Musculoskeletal discomfort; Nausea; Petechiae; Pharyngitis; Platelet count decreased; Pneumonia; Renal failure; Rhinitis; Sepsis; Sinusitis; Stomatitis; Upper respiratory tract infection; Urinary tract infection; Urine abnormality; Urine analysis abnormal; Vomiting; White blood cell count decreased","atc_codes":"L01DB07","group":"Drug","drug_type":"","target":["T001","T002","T408"],"function":["F0108","F0201","F0303"],"references":["RC04092","RC04216","RC04340","RC04464","RC04588"]},{"compound_ID":"D0085","name":"Muraglitazar","synonyms":"Muraglitazar; 331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; W1MKM70WQI; CHEMBL186179; BMS 298585; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; IRLWJILLXJGJTD-UHFFFAOYSA-N; Tox21_113946; BDBM50150998; ZINC49650290; AKOS030255656; NCGC00262954-01; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; ZINC000049650290; LS-190838; RT-013967; CAS-331741-94-7; FT-0672555; D05091; [C14]-2-((4-methoxyphenoxy)carbonyl)acetic acid; J-019059; Q6937233; (((4-Methoxyphenoxy)carbonyl)(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)amino)acetic acid; ((4-Methoxy-phenoxycarbonyl)-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-amino)-acetic acid; 2-[(4-methoxyphenoxycarbonyl)({3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}methyl)amino]acetic acid; 2-[(4-methoxyphenoxycarbonyl)({4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}methyl)amino]acetic acid; Glycine, N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-; N-[[4-methoxyphenoxy)carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)-ethoxy]phenyl]methyl]glycine","trade_name":"","abbrev_name":"","description":"","molecular_formula":"C29H28N2O7","molecular_weight":"516.5","state":"solid","clearance":"","volume_of_distribution":"","route_of_elimination":"","protein_binding":"","half_life":"","absorption":"","cid":"206044","classification":"Others","indications":"","side_effects":"","atc_codes":"","group":"Drug","drug_type":"","target":[],"function":[],"references":[]},{"compound_ID":"D0086","name":"Nabumetone","synonyms":"nabumetone; 42924-53-8; Relafen; 4-(6-methoxynaphthalen-2-yl)butan-2-one; Arthaxan; Nabumetona; Relifex; Listran; Relifen; nabumeton; Consolan; Mebutan; Balmox; Relif; 4-(6-Methoxy-2-naphthyl)-2-butanone; Dolsinal; Flambate; Nabumetonum; Unimetone; Prodac; Nabumetonum [INN-Latin]; Nabuser; BRL-14777; 4-(6-Methoxy-2-naphthalenyl)-2-butanone; UNII-LW0TIW155Z; BRL 14777; MLS000069541; 4-(2-Methoxynaphthalen-6-yl)butan-2-one; 2-Butanone, 4-(6-methoxy-2-naphthalenyl)-; BRN 2103472; LW0TIW155Z; SMR000058835; CHEBI:7443; BLXXJMDCKKHMKV-UHFFFAOYSA-N; BRL14777; NCGC00016853-01; AK-86115; CAS-42924-53-8; DSSTox_CID_25472; DSSTox_RID_80901; DSSTox_GSID_45472; 4-[6-methoxy-2-naphthyl]-2-butanone; SR-01000759138; CCRIS 8108; Nabumetone [USAN:BAN:INN:JAN]; Nabumatone Form II; Relafen (TN); Nabumetone [USAN:USP:INN:BAN:JAN]; Spectrum_001486; Opera_ID_765; Prestwick0_000909; Prestwick1_000909; Prestwick2_000909; Prestwick3_000909; Spectrum2_001969; Spectrum4_000174; Spectrum5_001286; cid_4409; SCHEMBL2256; CHEMBL1070; BSPBio_000758; KBioGR_000687; KBioSS_001966; MLS001076325; BIDD:GT0104; DivK1c_000850; SPECTRUM1503650; SPBio_002097; SPBio_002957; Nabumetone, analytical standard; BPBio1_000834; GTPL7245; Nabumetone (JP17/USP/INN); DTXSID4045472; BDBM40128; CTK8B4843; HMS502K12; KBio1_000850; KBio2_001966; KBio2_004534; KBio2_007102; ZINC20221; NINDS_000850; HMS1570F20; HMS1922G10; HMS2090D13; HMS2093I05; HMS2097F20; HMS2230H12; HMS3259I16; HMS3652M04; HMS3714F20; Pharmakon1600-01503650; BCP12152; HY-B0559; Tox21_110647; ANW-46490; CCG-39507; MFCD00079518; NSC758623; s4051; AKOS009529199; Tox21_110647_1; 4-(6-methoxy-2-naphthyl)butan-2-one; API0003472; CS-2669; DB00461; KS-1371; NC00579; NSC-758623; IDI1_000850; NCGC00016853-02; NCGC00016853-03; NCGC00016853-06; NCGC00095063-01; NCGC00095063-02; AC-19025; BC966361; CC-32257; CPD000058835; LS-46825; M727; SAM002564225; SC-77045; SBI-0051869.P002; AX8142896; ST2405403; TC-135235; AB00052392; AM20040460; FT-0629765; SW197312-3; D00425; AB00052392-13; AB00052392_14; AB00052392_15; 924N538; C-13097; Q425207; SR-01000759138-2; SR-01000759138-3; BRD-K65146499-001-04-8; BRD-K65146499-001-14-7; Nabumetone, British Pharmacopoeia (BP) Reference Standard; Nabumetone, European Pharmacopoeia (EP) Reference Standard; Nabumetone, United States Pharmacopeia (USP) Reference Standard","trade_name":"","abbrev_name":"","description":"","molecular_formula":"C15H16O2","molecular_weight":"228.29","state":"solid","clearance":"6-MNA has an apparent steady-state clearance of 20 - 30 mL/min.[label]","volume_of_distribution":"The Vd of 6-MNA reported after administration of a single dose is 0.1-0.2 L/kg or approximately 5-10 L.[A178903] Vdss reported in official product labeling is approximately 53 L.[label,L6466]","route_of_elimination":"Most drug is eliminated via hepatic metabolism with minimal to no parent drug detectable in the plasma.[label,A178903] 80% of the dose is then excreted by the kidneys and 10% in the feces. It does not appear to undergo enterohepatic recirculation.","protein_binding":"6-MNA is over 99% bound to plasma proteins, likely albumin.[label,A178903] The unbound fraction is 0.1-0.2% and remains proportional in the dose range of 1000-2000mg","half_life":"6-MNA has a mean half-life of 24 hours with a range of 19-36 hours.[label]","absorption":"Nabumetone is well-absorbed from the GI tract and undergoes significant first pass metabolism resulting in approximately 35% being converted to the active metabolite, 6-MNA.[label,A178903] Tmax for 6-MNA varies widely with a mean values of 3 and 11 hours reported in official product monographs, and described as 9-12 hours in published literature [label,L6466,A178903] Administration with food increases Cmax by 33% and increases absorption rate.[label,A178903] If formulated as a suspension the Cmax increases and the Tmax is reduced by 0.8 hours while the all other pharmacokinetic parameters remain unchanged.[A178903]","cid":"4409","classification":"M","indications":"Arthritis; Osteoarthritis; Rheumatoid arthritis","side_effects":"Abdominal pain (0.12); Weight increased (0.007); Asthenia; Dizziness; Feeling abnormal","atc_codes":"M01AX01","group":"Drug","drug_type":"","target":[],"function":[],"references":[]},{"compound_ID":"D0087","name":"Naltrexone","synonyms":"naltrexone; 16590-41-3; ReVia; Vivitrol; N-Cyclopropylmethylnoroxymorphone; Celupan; Vivitrex; Naltrexonum; Naltrexona; Naltrexonum [INN-Latin]; Naltrexona [INN-Spanish]; UNII-5S6W795CQM; N-Cyclopropylmethyl-14-hydroxydihydromorphinone; Naltrexone [USAN:INN:BAN]; CCRIS 3506; HSDB 6750; 17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; EINECS 240-649-9; UM-792; 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one; BRN 3596648; 5S6W795CQM; CHEBI:7465; (-)-Naltrexone; Nemexin; EN-1639A [AS HYDROCHLORIDE]; DSSTox_CID_26313; DSSTox_RID_81532; DSSTox_GSID_46313; Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-; Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5alpha)-; (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one; Naltrexone base anhydrous; CAS-16590-41-3; Naltrexon; (-)naltrexone; PTI-555; NCGC00162274-02; Vivitrol (TN); naltrexone (ReVia); PubChem24168; (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride; Naltrexone (USAN/INN); Prestwick0_000116; Prestwick1_000116; Prestwick2_000116; Prestwick3_000116; US9107954, naltrexone; SCHEMBL34681; BSPBio_000132; BIDD:GT0405; CHEMBL19019; SPBio_002071; BPBio1_000146; GTPL1639; ZINC1773; DTXSID4046313; BDBM60212; cid_5485201; DQCKKXVULJGBQN-XFWGSAIBSA-N; cyclopropylmethyl(dihydroxy)[?]one; HMS2089O11; BCP07022; Tox21_112007; BDBM50000787; PDSP2_000847; AKOS015994596; Tox21_112007_1; CS-0880; DB00704; HS-0002; MCULE-7032963403; SMP1_000206; NCGC00024427-03; NCGC00024427-04; NCGC00024427-05; HY-76711; LS-92094; SC-94535; FT-0696752; C07253; D05113; W-5099; 88088-EP2270005A1; 88088-EP2275420A1; 88088-EP2298761A1; 88088-EP2298776A1; 88088-EP2305648A1; AB00174152-14; AB00174152_17; AR-270/43507956; Q409587; BRD-K88172511-003-21-1; BRD-K88172511-310-03-8; (5alpha)-17-(Cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-one; 3,14-dihydroxy-17-(cyclopropylmethyl)-4,5alpha-epoxymorphinan-6-one; 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxmorphinan-6-one, (5.alpha.)-; Naltrexone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18)-trien-14-one; (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-bis(oxidanyl)-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride; (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one; 4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0~1,13~.0~5,17~.0~7,18~]octadeca-7(18),8,10-trien-14-one","trade_name":"","abbrev_name":"","description":"","molecular_formula":"C20H23NO4","molecular_weight":"341.4","state":"solid","clearance":"* ~ 3.5 L/min [after IV administration]","volume_of_distribution":"* 1350 L [intravenous administration]","route_of_elimination":"Both parent drug and metabolites are excreted primarily by the kidney (53% to 79% of the dose), however, urinary excretion of unchanged naltrexone accounts for less than 2% of an oral dose and fecal excretion is a minor elimination pathway. The renal clearance for naltrexone ranges from 30 to 127 mL/min and suggests that renal elimination is primarily by glomerular filtration.","protein_binding":"21% bound to plasma proteins over the therapeutic dose range.","half_life":"4 hours for naltrexone and 13 hours for the active metabolite 6 beta-naltrexol.","absorption":"Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.","cid":"5360515","classification":"N; A","indications":"Alcohol abuse; Alcoholism; Drug dependence","side_effects":"Anxiety (0.02); Vomiting (0.03); Headache; Nausea","atc_codes":"N02AA56; N07BB04; A08AA62","group":"Drug","drug_type":"","target":[],"function":[],"references":[]},{"compound_ID":"D0088","name":"Naproxen","synonyms":"NAPROXEN; 22204-53-1; (S)-Naproxen; (+)-Naproxen; Naprosyn; Naproxene; Equiproxen; Aleve; (S)-(+)-Naproxen; Laraflex; Naproxeno; Naproxenum; d-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; Calosen; Naprosyne; Nycopren; Bonyl; Naixan; Reuxen; Axer; (+)-(S)-Naproxen; Ec-Naprosyn; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Acusprain; Anexopen; Arthrisil; Artrixen; Artroxen; Bipronyl; Clinosyn; Danaprox; Flexipen; Leniartil; Novonaprox; Anaprox; Apronax; Artagen; Atiflan; Congex; Daprox; Genoxen; Lefaine; Nafasol; Nalyxan; Napflam; Napmel; Naposin; Napren; Naprius; Veradol; Fuxen; Naxen; Naxyn; Xenar; Dysmenalgit N; Apo-Naproxen; Floginax; Headlon; Napratec; Naprontag; Narocin; Naxopren; Prafena; Priaxen; Pronaxen; Rheumaflex; Saritilron; Sinartrin; Soproxen; Sutolin; Tohexen; Traumox; Flexen; Napxen; Noflam; Patxen; Rahsen; Sinton; Sutony; Velsay; Vinsen; Narma; Roxen; Anax; (S)-2-(6-Methoxy-2-naphthyl)propionic acid; Flanax Forte; (+)-2-(6-Methoxy-2-naphthyl)propionic acid; Naprosyn LLE; Napren E; Proxen LE; Naxen F; Proxen LLE; U-Ritis; naproxen(+); (+)-2-(Methoxy-2-naphthyl)-propionic acid; RS-3540; Naprosyn LLE Forte; Naproxi 250; Naproxi 500; (S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Naxyn 250; Naxyn 500; (S)-2-(6-Methoxy-2-naphthyl)propanoic acid; Equiproxen (Veterinary); Apo-Napro-NA; Naproxene [INN-French]; Naproxenum [INN-Latin]; Naproxeno [INN-Spanish]; d-2-(6-Methoxy-2-naphthyl)propionic acid; (+)-2-(Methoxy-2-naphthyl)-propionsaeure; UNII-57Y76R9ATQ; (+)-(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; (S)-(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Dysmenalgit; Diocodal; Prexan; CG 3117; CCRIS 5265; CHEBI:7476; HSDB 3369; EINECS 244-838-7; CHEMBL154; RS 3540; (+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; 57Y76R9ATQ; d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure; (2S)-2-(6-methoxy-2-naphthyl)propanoic acid; CMWTZPSULFXXJA-VIFPVBQESA-N; Laser; (+)-2-(Methoxy-2-naphthyl)-propionsaeure [German]; MFCD00010500; Propionic acid, 2-(6-methoxy-2-naphthyl)-, (+)-; d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure [German]; Duk; 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (+)-; 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (S)-; Methoxypropiocin; CAS-22204-53-1; (S)-2-(6-Methoxy-naphthalen-2-yl)-propionic acid; (S)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid; Naprosin; 26159-31-9; Xenar-CR; (s)-(+)-6-methoxy-alpha-methyl-2-naphthalene acetic acid; 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (S)-; Naprolag; Naprosine; Naprosy; Panoxen; Proxine; Mnpa; SR-01000075977; 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (.alpha.S)-; DL Naproxen; Naproxen [USAN:BAN:INN:JAN]; Naprosyn (TN); Naproxen,(S); NPS; Prestwick_349; Naproxen [USAN:USP:INN:BAN:JAN]; PubChem8102; Spectrum_000977; 4or0; 4po0; (S)-(+)-Naproxene; Prestwick0_000791; Prestwick1_000791; Prestwick2_000791; Spectrum2_001043; Spectrum3_000514; Spectrum4_000069; Spectrum5_001327; (+)NAPROXEN; Naproxen2-(6-Methoxy-naphthalen-2-yl)-propionic acid; Epitope ID:139974; UPCMLD-DP001; 2-(6-Methoxy-naphthalen-2-yl)-propionic acid(Naproxen); EC 244-838-7; SCHEMBL3046; DSSTox_CID_20686; DSSTox_RID_79542; DSSTox_GSID_40686; Lopac0_000792; BSPBio_002067; KBioGR_000597; KBioSS_001457; KSC911E2L; ARONIS24306; BIDD:GT0062; DivK1c_000242; SPECTRUM1500425; Naproxen (JP17/USP/INN); SPBio_000966; SPBio_002861; GTPL5230; DTXSID4040686; UPCMLD-DP001:001; CMWTZPSULFXXJA-VIFPVBQESA-; CTK8B1225; HMS500M04; KBio1_000242; KBio2_001457; KBio2_004025; KBio2_006593; KBio3_001567; KS-00002WWU; Naproxen 1.0 mg/ml in Methanol; NINDS_000242; HMS1920P13; HMS2089N21; HMS2091H12; HMS3649M13; Pharmakon1600-01500425; ZINC105216; ACT02593; Tox21_301953; ANW-24773; BDBM50339185; CCG-40130; NSC750183; NSC757239; AKOS005267223; AC-1363; CS-2163; DB00788; MCULE-2589082817; ME-0100; NSC-750183; NSC-757239; RTR-010461; IDI1_000242; Naproxen solution 1.0 mg/ml in methanol; NCGC00016759-01; NCGC00016759-02; NCGC00016759-03; NCGC00021127-01; NCGC00161591-01; NCGC00255562-01; BR-72928; HY-15030; SC-02561; (+)-2-(Methoxy-2-naphthyl)-propionsaure; Naproxen, meets USP testing specifications; SBI-0050769.P004; AB1009325; LS-124738; ST2408284; AM20060551; FT-0082415; FT-0602835; M1021; W4580; Naproxen, VETRANAL(TM), analytical standard; (S)-2-(6-methoxy-2-naphthyl)-propionic acid; 04N531; C01517; D00118; J10145; M-5280; (2S)-2-(6-methoxy(2-naphthyl))propanoic acid; AB00052049-04; AB00052049_05; (+)(S)2-(6-methoxy-2-naphthyl)-propionic acid; 2-(6-Methoxy-2-naphthyl)propanoic acid , (+)-; SR-01000003110; Q-201447; Q1215575; SR-01000003110-5; SR-01000075977-3; SR-01000075977-4; (+)-6-Methoxy-.alpha.-methyl-2-napthaleneacetic acid; BRD-K59197931-001-02-9; BRD-K59197931-001-03-7; BRD-K59197931-236-09-6; SR-01000075977-10; (+)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid; (alphas)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid; (S)-(+)-2-(6-methoxy-naphthalen-2-yl)-propionic acid; (S)-6-Methoxy-.alpha.-methyl-2-naphthalene acetic acid; Naproxen, British Pharmacopoeia (BP) Reference Standard; Naproxen, European Pharmacopoeia (EP) Reference Standard; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; Naproxen; (S)-(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid, 98%; 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (+)-; Naproxen, United States Pharmacopeia (USP) Reference Standard; 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (+)- (8CI); Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material; Naproxen solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; d-Naproxen; (2S)-2-(6-Methoxynaphthalen-2-yl)propanoic acid; (S)-6-Methoxy-?-methyl-2-naphthaleneacetic Acid; d-2-(6-Methoxy-2-naphthyl)propionic Acid; InChI=1/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1","trade_name":"Aleve","abbrev_name":"","description":"nonsteroidal anti-inflammatory drug (NSAID) ; nonselective COX inhibitor; propionic acid class","molecular_formula":"C14H14O3","molecular_weight":"230.26","state":"solid","clearance":"Naproxen is cleared at a rate of 0.13 mL/min/kg.[L6582][L6583]","volume_of_distribution":"Naproxen has a volume of distribution of 0.16 L/kg.[L6582][L6583]","route_of_elimination":"After oral administration, about 95% of naproxen and it's metabolites can be recovered in the urine with 66-92% recovered as conjugated metabolite and less than 1% recovered as naproxen or desmethylnaproxen.[A179197][L6582][L6583] Less than 5% of naproxen is excreted in the feces.[L6582][L6583]","protein_binding":"Naproxen is highly protein bound with >99% of the drug bound to albumin at therapeutic levels.[L6582][L6583]","half_life":"The half-life of naproxen is reported to be 12-17 hours.[A178975]","absorption":"Naproxen is available as a free acid and sodium salt.[A179098] At comparable doses, (naproxen 500 mg = naproxen sodium 550 mg) they differ slightly in their rates of absorption, but otherwise they are therapeutically and pharmacologically equivalent.[A179098] Naproxen sodium achieves a peak plasma concentration after 1 hour, while peak plasma concentration is observed after 2 hours with naproxen (free acid).[A179098] There are no differences between the 2 forms in the post-absorption phase pharmacokinetics.[A179098] The difference in initial absorption should be considered when treating acute pain, since naproxen sodium may offer a quicker onset of action.[A179098]\n\nOverall, naproxen is rapidly and completely absorbed when administered orally and rectally.[A179110][A179098] Food may contribute to a delay in the absorption of orally administered naproxen, but will not affect the extent of absorption.[A179098]","cid":"156391","classification":"G; M","indications":"Abdominal discomfort; Ankylosing spondylitis; Body temperature increased; Fibromyalgia; Gastrointestinal haemorrhage; Gouty arthritis; Headache; Inflammation; Joint swelling; Juvenile idiopathic arthritis; Ligament sprain; Muscle spasms; Musculoskeletal disorder; Musculoskeletal stiffness; Nasopharyngitis; Nephropathy; Osteoarthritis; Procedural pain; Rheumatic disorder; Rheumatoid arthritis; Rhinitis; Rotator cuff syndrome; Spinal osteoarthritis; Spondylitis; Tendonitis; Toothache; Ulcer; Uterine pain; Vasculitis","side_effects":"Asthenia (0); Influenza (0.1)","atc_codes":"M01AE56; G02CC02; M01AE52; M01AE02; M02AA12","group":"Drug","drug_type":"","target":[],"function":["F010502"],"references":["RC03808"]},{"compound_ID":"D0089","name":"Nefazodone","synonyms":"nefazodone; 83366-66-9; Nefazodona; Nefazodonum; Nefazodonum [Latin]; Nefazodona [Spanish]; Nefazodone [INN:BAN]; UNII-59H4FCV1TF; 1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one; CHEMBL623; 59H4FCV1TF; CHEBI:7494; VRBKIVRKKCLPHA-UHFFFAOYSA-N; Nefadar; 1-(3-(4-(3-Chlorophenyl)piperazin-1-yl)propyl)-3-ethyl-4-(2-phenoxyethyl)-1H-1,2,4-triazol-5(4H)-one; 1-(3-(4-(3-Chlorpheyl-1-piperazinylpropyl)-3-ethyl-4,5-dihydro-4-(2-phenoxyethyl)-1,2,4-triazol-5-on; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; 1-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-3-ethyl-4-(2-phenoxyethyl)-4,5-dihydro-1H-1,2,4-triazol-5-one; 3H-1,2,4-Triazol-3-one, 2,4-dihydro-2-3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-5-ethyl-4-(2-phenoxyethyl)-; 3H-1,2,4-Triazol-3-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-; Nefazodone (INN); SMR000550487; NCGC00165846-02; C25H32ClN5O2; SR-01000759312; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one; SCHEMBL35089; MLS001165769; MLS001195657; BIDD:GT0789; GTPL7247; DTXSID2023357; HMS2090D17; HMS2231I17; HMS3264K04; HMS3372C02; Pharmakon1600-01502314; ZINC538065; BCP30990; BDBM50069447; NSC760344; AKOS015907198; API0003523; CCG-213026; DB01149; NSC-760344; VA11366; Dutonin pound>> Nefadar pound>> Serzone; NCGC00165846-01; NCGC00165846-03; 2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one; 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-4-(2-phenoxyethyl)-2H-1,2,4-triazol-3(4H)-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-[2-(phenyloxy)ethyl]-2,4-dihydro-3H-1,2,4-triazol-3-one; AX8022765; LS-156497; FT-0654783; C07256; D08257; AB00640019-14; AB00640019_15; 117201-EP2275420A1; 117201-EP2298764A1; 117201-EP2298765A1; 117201-EP2298776A1; 366N669; A840565; L001196; Q416632; SR-01000759312-5; BRD-K90789829-003-03-3; 2-(3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl)-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one #; 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one","trade_name":"Serzone","abbrev_name":"triazolopyridine","description":"antidepressant","molecular_formula":"C25H32ClN5O2","molecular_weight":"470","state":"solid","clearance":"","volume_of_distribution":"* 0.22 to 0.87 L/kg","route_of_elimination":"Nefazodone is extensively metabolized after oral administration by n-dealkylation and aliphatic and aromatic hydroxylation, and less than 1% of administered nefazodone is excreted unchanged in urine.","protein_binding":"Greater than 99% (in vitro, human plasma proteins).","half_life":"2-4 hours","absorption":"Nefazodone is rapidly and completely absorbed. Its absolute bioavailability is low (about 20%).","cid":"4449","classification":"N","indications":"Agitation; Asthenia; Bradyphrenia; Decreased interest; Depressed mood; Depression; Disturbance in attention; Drug abuse; Dysphoria; Fatigue; Feeling guilty; Hypersomnia; Insomnia; Mental disability; Suicidal ideation; Suicide attempt","side_effects":"Agitation (0.012); Nausea (0.035)","atc_codes":"N06AX06","group":"Drug","drug_type":"","target":["T001","T002","T004","T005","T019"],"function":["F020103","F020403"],"references":["RC00162","RC00163","RC00164","RC00165","RC00166","RC00937","RC03627","RC04944"]},{"compound_ID":"D0090","name":"Nevirapine","synonyms":"nevirapine; 129618-40-2; Viramune; BI-RG-587; Viramune XR; NVP; BIRG 0587; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; UNII-99DK7FVK1H; 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; Nevirapine anhydrous; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one; Nevirapine (Viramune); BI-RG 587; BIRG-0587; HSDB 7164; CHEMBL57; NEV; NSC 641530; 99DK7FVK1H; 11-CYCLOPROPYL-4-METHYL-5H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6(11H)-ONE; MLS000084585; C15H14N4O; CHEBI:63613; NQDJXKOVJZTUJA-UHFFFAOYSA-N; Nevirapine, 98%; NSC641530; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; 6H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-; NCGC00065890-02; SMR000048458; DSSTox_CID_10787; DSSTox_RID_78889; DSSTox_GSID_31797; 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one; BIRG587; Nevirapine [USAN:INN]; Viramune(TM); Viramune (TN); CAS-129618-40-2; Nevirapine & CD4-IgG; Nevirapine & PRO 140; Nevirapine (JAN/USP/INN); 11-cyclopropyl-4-methyl-5H-dipyrido[[?],[?]][1,4]diazepin-6-one; BIRG 587; BIRG-587; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; 11-cyclopropyl-4-methyl-5H-dipyrido[2,3-b:3',2'-e][1,4]diazepin-6-one; Viramune IR; 1vrt; 2hny; Nevirapine,(S); Nevirapine [USAN:USP:INN:BAN]; BI-RG-587 & CD4-IgG; Opera_ID_934; Viramune;BI-RG 587; SCHEMBL3318; MLS000759409; MLS001055309; MLS001201730; MLS001424058; MLS006011423; BIDD:GT0326; BDBM1434; ZINC4778; DTXSID7031797; CTK8E7455; KS-00000KZF; HMS2051J09; HMS2231O23; HMS3264D21; HMS3371E03; HMS3393J09; HMS3655I08; HMS3715B10; Pharmakon1600-01503842; ALBB-027264; BCP05587; Tox21 110982; Tox21_110982; Tox21_200770; AC-643; BBL010768; MFCD00866928; NSC759902; STK580320; AKOS005504351; Tox21_110982_1; AB07544; CCG-100939; CS-2252; DB00238; KS-5019; LS-2289; MCULE-8608154492; NC00189; NSC-641530; NSC-759902; NCGC00065890-03; NCGC00065890-04; NCGC00065890-05; NCGC00065890-07; NCGC00258324-01; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); AK143126; CPD000048458; H954; HY-10570; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; SAM001246551; SC-17266; SY009679; BI-RG 587;NSC 641530;NVP; AB0013383; AB2000266; DB-041930; RT-014690; FT-0607215; N0922; R3924; S1742; ST24038235; SW197569-2; 11-Cyclopropyl-4-methyl-5H-dipyrido[3,2-b; MFCD00866928 (98%); C07263; D00435; AB00393001-13; AB00393001-15; AB00393001_16; AB00393001_17; 618N402; Q263713; F2173-0607; Z1695906730; BI-RG-587; BIRG 0587; BIRG587; HSDB 7164; NSC 641530; NVP; Nevirapine (anhydrous), European Pharmacopoeia (EP) Reference Standard; Nevirapine anhydrous, United States Pharmacopeia (USP) Reference Standard; Nevirapine solution, 1.0 mg/mL in methanol, certified reference material; Nevirapine, Pharmaceutical Secondary Standard; Certified Reference Material; 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido-[3,2-b:2',3'-e][1,4]diazepin-6-one; 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b :2',3'-e][1,4 ]diazepin-6-one; 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2 ,3 -e][1,4]diazepin-6-one; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2', 3'-e][1,4]diazepin-6-one; 5H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 5,11-dihydro-11-cyclopropyl-4-methyl-; 6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-; Nevirapine for peak identification, European Pharmacopoeia (EP) Reference Standard; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2 inverted exclamation mark ,3 inverted exclamation mark -e][1,4]diazepin-6-one; 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0(3),]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one; 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-10-one","trade_name":"","abbrev_name":"","description":"","molecular_formula":"C15H14N4O","molecular_weight":"266.3","state":"solid","clearance":"","volume_of_distribution":"* 1.21 ± 0.09 L/kg [apparent volume of distribution, healthy adults, IV] \nNevirapine is capable of crossing the placenta and is found in breast milk.","route_of_elimination":"Thus cytochrome P450 metabolism, glucuronide conjugation, and urinary excretion of glucuronidated metabolites represent the primary route of nevirapine biotransformation and elimination in humans. Only a small fraction (<5%) of the radioactivity in urine (representing <3% of the total dose) was made up of parent compound; therefore, renal excretion plays a minor role in elimination of the parent compound.","protein_binding":"60% bound to plasma protein.","half_life":"45 hours","absorption":"Nevirapine is readily absorbed (greater than 90%) after oral administration in healthy subjects and adults with HIV-1 infection. The absolute bioavailability in healthy adults following a single dose administration is 93 ± 9% (mean ± SD) for a 50 mg tablet and 91 ± 8% for an oral solution. Peak plasma nevirapine concentrations of 2 ± 0.4 mcg/mL (7.5 micromolar) were attained by 4 hours following a single 200 mg dose. Nevirapine tablets and suspension have been shown to be comparably bioavailable and interchangeable at doses up to 200 mg. When the oral tablet is given with a high-fat meal, the extent of absorption is compared to that of the fasted-state.","cid":"4463","classification":"J","indications":"Acquired immunodeficiency syndrome; Autoimmune disorder; Dermatitis; Hepatotoxicity; Infection; Rash","side_effects":"Arthralgia (0.02); Stevens-Johnson syndrome (0.003); Abdominal pain; Agranulocytosis; Anaemia; Asthenia; Body temperature increased; Dermatitis; Diarrhoea; Fatigue; Gastrointestinal pain; Headache; Hepatitis; Hepatotoxicity; Liver function test abnormal; Musculoskeletal discomfort; Myalgia; Nausea; Neutropenia; Rash","atc_codes":"J05AG01; J05AR07; J05AR05","group":"Drug","drug_type":"","target":[],"function":[],"references":[]},{"compound_ID":"D0091","name":"Nicotine","synonyms":"nicotine; L-Nicotine; (-)-Nicotine; 54-11-5; (S)-Nicotine; (S)-3-(1-methylpyrrolidin-2-yl)pyridine; (S)-(-)-Nicotine; Habitrol; Nicoderm; Nicotrol; 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine; Fumetobac; Micotine; Nicocide; Tendust; Nico-dust; Nicoderm Cq; Emo-nik; Nico-Fume; Nicotine alkaloid; Mach-Nic; Nic-Sal; Nicotine polacrilex; Nikotin [German]; Nikotyna [Polish]; Flux MAAG; Nicotina [Italian]; Ortho N-4 dust; Ortho N-5 dust; XL All Insecticide; Niagara P.A. dust; Nicorette; Nicotina; Nikotyna; Prostep; Destruxol orchid spray; Nicotrol Inhaler; Nicotrol NS; NICOTINE AND SALTS; 3-(N-Methylpyrollidino)pyridine; 3-(N-Methylpyrrolidino)pyridine; L-3-(1-Methyl-2-pyrrolidyl)pyridine; L(-)-nicotine; (-)-3-(1-Methyl-2-pyrrolidyl)pyridine; Ortho N-4 and N-5 dusts; (S)-3-(1-Methyl-2-pyrrolidinyl)pyridine; Nicotin; Caswell No. 597; Black leaf; Nicotine [BSI:ISO]; Tetrahydronicotyrine, DL-; RCRA waste number P075; 1-Methyl-2-(3-pyridyl)pyrrolidine; NSC 5065; UNII-6M3C89ZY6R; ENT 3,424; beta-Pyridyl-alpha-N-methylpyrrolidine; 3-(2-(N-methylpyrrolidinyl))pyridine; Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)-; CCRIS 1637; S-(-)-Nicotine; Nicotine (compounds related to); HSDB 1107; EINECS 200-193-3; MFCD00006369; UN1654; 3-(1-Methyl-2-pyrollidinyl)pyridine; (-)-3-(N-Methylpyrrolidino)pyridine; RCRA waste no. P075; EPA Pesticide Chemical Code 056702; beta-Pyridyl-alpha-N-methyl pyrrolidine; 3-(1-Methyl-2-pyrrolidinyl)pyridine; Pyrrolidine, 1-methyl-2-(3-pyridal)-; (S)-3-(N-methylpyrrolidin-2-yl)pyridine; AI3-03424; 6M3C89ZY6R; 3-((2S)-1-methylpyrrolidin-2-yl)pyridine; CHEBI:17688; Pyridine, 3-(tetrahydro-1-methylpyrrol-2-yl); SNICXCGAKADSCV-JTQLQIEISA-N; 1-Methyl-2-(3-pyridiyl)pyrrolidine; L-Nicotine, 99+%; DSSTox_CID_930; Nicotine [for single use]; NICOTINE-L (BASE); destruxol; Pyridine, 3-((2S)-1-methyl-2-pyrrolidinyl)-; Pyridine, 3-[(2S)-1-methyl-2-pyrrolidinyl]-; DSSTox_RID_75874; DSSTox_GSID_20930; Nicotine [USAN]; (-)-1-Methyl-2-(3-pyridyl)pyrrolidine; fumeto bac; Nicabate; Niquitin; Tabazur; Exodus; Nictoine patch; Nicoderm Patch; Nicotine Patch; Nicotine-D salicylate; CAS-54-11-5; DL-tetrahydronicotyrine; Habitrol (TN); Nicotine (USP); SMR000059074; Transdermal Nicotine; Nicotine [USP:BAN]; nicotine replacement patch; methyl-2-pyrrolidinyl)pyridine; Nicotinum; delta-Nicotine; Nicotine betadex; 1-methyl-2-(3-pyridal)-pyrrolidene; Nicotine [UN1654] [Poison]; a-N-methylpyrrolidine; Campbell's nico-soap; 3-N-methylpyrrolidine; R)-(+)-nicotine; a -N-methylpyrrolidine; CHEMBL3; 1uw6; alpha-N-methylpyrrolidine; Nicotine [UN1654]; (S)-(-)--nicotine; bmse000105; (2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine; EC 200-193-3; Nicotine polacrilex [USAN]; S-()-Nicotine-pyridine-d4; SCHEMBL20192; MLS001055457; MLS001335905; BIDD:GT0599; GTPL2585; DTXSID1020930; BDBM82070; CTK8F2098; HMS2230H17; HMS3259E16; Nicotine [UN1654] [Poison]; ZINC391812; HY-B0638; Nicotine 10 microg/mL in Methanol; Tox21_201814; Tox21_300174; Nicotine 100 microg/mL in Methanol; PDSP1_000113; PDSP1_000465; PDSP2_000463; PDSP2_000555; SBB012359; 1-methyl-2-(3-pyridal)-Pyrrolidine; AKOS016843798; 3-(1-methyl-2-pyrrolidinyl)-Pyridine; CCG-204892; CS-3999; DB00184; MCULE-8728421654; NC00577; SB12751; SDCCGMLS-0066911.P001; NCGC00090693-01; NCGC00090693-02; NCGC00090693-03; NCGC00090693-04; NCGC00090693-05; NCGC00090693-06; NCGC00090693-07; NCGC00090693-08; NCGC00090693-09; NCGC00254095-01; NCGC00259363-01; Pyrrolidine, 1-methyl-2-(3-pyridyl)-; (-)-Nicotine, >=99% (GC), liquid; CPD000059074; SAM002564224; SC-58411; ST069320; SBI-0050785.P003; CAS_29790-52-1; FT-0603228; FT-0672702; N0079; C00745; D03365; (-)-.beta.-Pyridyl-.alpha.-N-methylpyrrolidine; AB00694322_12; (-)-Nicotine, PESTANAL(R), analytical standard; 006N369; 3-[(1R)-1beta-Methylpyrrolidine-2alpha-yl]pyridine; 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE; J-500021; SR-05000001762-5; BRD-K05395900-322-02-1; BRD-K05395900-322-04-7; Pyridine, 3-(tetrahydro-1-methylpyrrol-2-yl), (S)-; Q28086552; Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- (9CI); Z1954805269; 434F7990-3240-4A43-ACEC-E6CC1E495FA0; (-)-Nicotine solution, 1.0 mg/mL, analytical standard, for drug analysis; (-)-Nicotine solution, 100 mug/mL in acetonitrile, PESTANAL(R), analytical standard; S(-)-Nicotine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material","trade_name":"","abbrev_name":"","description":"nicotinic acetylcholine receptors (nAChRs) agonist; stimulant and potent parasympathomimetic alkaloid; naturally produced in the nightshade family of plants (most notably in tobacco);","molecular_formula":"C10H14N2","molecular_weight":"162.23","state":"liquid","clearance":"* 1.2 L/min [healthy adult smoker]","volume_of_distribution":"* 2 to 3 L/kg","route_of_elimination":"About 10% of the nicotine absorbed is excreted unchanged in the urine.","protein_binding":"Less than 5%","half_life":"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours","absorption":"Absorption of nicotine through the buccal mucosa is relatively slow and the high and rapid rise followed by the decline in nicotine arterial plasma concentrations seen with cigarette smoking are not achieved with the inhaler. About 10% of absorbed nicotine is excreted unchanged in urine.","cid":"89594","classification":"N","indications":"Acute coronary syndrome; Angina pectoris; Arrhythmia; Coronary artery disease; Drug withdrawal syndrome; Eczema; Endocrine disorder; Gangrene; Hepatic failure; Hypersensitivity; Liver disorder; Local reaction; Malignant hypertension; Myocardial infarction; Nicotine dependence; Non-tobacco user; Palpitations; Peptic ulcer; Peripheral vascular disorder; Pregnancy; Prinzmetal angina; Rash generalised; Renal failure; Renal impairment; Sensitisation; Skin disorder; Sleep disorder; Thromboangiitis obliterans; Urticaria; Vasodilation procedure","side_effects":"Application site reaction (0.176); Pain (0.021); Abdominal pain; Acne; Arthralgia; Back pain; Confusional state; Dermatitis; Diarrhoea; Dysgeusia; Dysmenorrhoea; Dyspepsia; Dyspnoea; Feeling abnormal; Flatulence; Gastrointestinal pain; Headache; Menstrual disorder; Mouth ulceration; Musculoskeletal discomfort; Myalgia; Nausea; Oedema; Palpitations; Paraesthesia; Pruritus; Rash; Stomatitis; Tongue disorder; Tooth disorder; Vertigo","atc_codes":"N07BA01","group":"Drug","drug_type":"","target":["T001","T002","T408"],"function":["F0108","F0201","F02010203","F02010204","F02010205","F0303","F0308"],"references":["RC01286","RC01287","RC01288","RC01289","RC03700","RC04097","RC04221","RC04345","RC04469","RC04593"]},{"compound_ID":"D0092","name":"Nimesulide","synonyms":"nimesulide; 51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Aulin; Flogovital; Sulidene; Nimed; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; R-805; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; HYWYRSMBCFDLJT-UHFFFAOYSA-N; NCGC00015725-02; SMR000058484; CAS-51803-78-2; DSSTox_CID_17250; DSSTox_RID_79316; DSSTox_GSID_37250; W-105866; C13H12N2O5S; Antifloxil; Nimesulida; Nimesulidum; Guaxan; NIM; Nimesulide [BAN:INN]; Nimesulide [INN:BAN]; SR-01000000218; Aldoron; Nimedex; Orthobid; CCRIS 8225; Nise Gel; Nimesulide,(S); Prestwick_618; Spectrum_001577; Nimesulide (JAN/INN); Opera_ID_1247; Prestwick0_000194; Prestwick1_000194; Prestwick2_000194; Prestwick3_000194; Spectrum2_001541; Spectrum3_001576; Spectrum4_000178; Spectrum5_000964; Lopac-N-1016; N-(4-nitro-2-phenoxy-phenyl)methanesulfonamide; Lopac0_000855; SCHEMBL24882; BSPBio_000147; BSPBio_001103; BSPBio_003112; KBioGR_000443; KBioGR_000695; KBioSS_000443; KBioSS_002057; MLS001148268; DivK1c_000693; SPECTRUM1503231; SPBio_001382; SPBio_002068; N-(4-nitro-2-phenoxyphenyl); BPBio1_000163; GTPL7401; NIM-03; DTXSID3037250; BCBcMAP01_000034; HMS502C15; KBio1_000693; KBio2_000443; KBio2_002057; KBio2_003011; KBio2_004625; KBio2_005579; KBio2_007193; KBio3_000825; KBio3_000826; KBio3_002612; NINDS_000693; Bio2_000382; Bio2_000862; HMS1362G05; HMS1568H09; HMS1792G05; HMS1922K17; HMS1990G05; HMS2089B14; HMS2095H09; HMS2234K19; HMS3262L11; HMS3269G17; HMS3371J19; HMS3403G05; HMS3414P09; HMS3649A04; HMS3655D13; HMS3678P07; HMS3712H09; Pharmakon1600-01503231; BCP10076; HY-B0363; ZINC4617749; Tox21_110207; Tox21_301850; Tox21_500855; BDBM50056999; CCG-39319; CN0038; EI-287; MFCD00079470; NSC758412; s2040; STL018679; AKOS015897356; Tox21_110207_1; AC-4524; CS-2420; DB04743; KS-1277; LP00855; MCULE-4217888990; NSC-758412; IDI1_000693; IDI1_002137; NCGC00015725-01; NCGC00015725-03; NCGC00015725-04; NCGC00015725-05; NCGC00015725-06; NCGC00015725-07; NCGC00015725-08; NCGC00015725-09; NCGC00015725-10; NCGC00015725-11; NCGC00015725-12; NCGC00015725-13; NCGC00015725-15; NCGC00015725-16; NCGC00021842-03; NCGC00021842-04; NCGC00021842-05; NCGC00021842-06; NCGC00021842-07; NCGC00021842-08; NCGC00255661-01; NCGC00261540-01; AK163559; LS-90290; SC-17925; SBI-0050831.P003; AB2000444; DB-052029; AB00052332; EU-0100855; FT-0630650; N0984; ST51015069; SW196785-3; (methylsulfonyl)(4-nitro-2-phenoxyphenyl)amine; D01049; N 1016; Q20994; AB00052332-16; AB00052332_17; AB00052332_18; n-(4-nitro-2-phenoxy-phenyl)-methanesulfonamide; N-[4-nitro-2-(phenoxy)phenyl]methanesulfonamide; 803N782; A828786; SR-01000000218-2; SR-01000000218-6; SR-01000000218-7; BRD-K76775527-001-06-2; BRD-K76775527-001-18-7; SR-01000000218-11; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)- (9CI); Nimesulide, European Pharmacopoeia (EP) Reference Standard; Nimesulide, Pharmaceutical Secondary Standard; Certified Reference Material; Nimesulide for peak identification, European Pharmacopoeia (EP) Reference Standard","trade_name":"","abbrev_name":"","description":"analgesics; a relative COX-2 selective, non-steroidal anti-inflammatory drug (NSAID)","molecular_formula":"C13H12N2O5S","molecular_weight":"308.31","state":"solid","clearance":"","volume_of_distribution":"","route_of_elimination":"Renal (50%), fecal (29%)","protein_binding":">97.5%","half_life":"1.8–4.7 hours","absorption":"Rapidly absorbed following oral administration.","cid":"4495","classification":"M","indications":"","side_effects":"","atc_codes":"M02AA26; M01AX17","group":"Drug","drug_type":"","target":["T001","T002","T387001","T387002","T408"],"function":["F01","F010401","F0105","F0108","F0201","F020101","F02010102","F02010103","F02010202","F0206","F021202","F0221","F0303","F05","F0504","F070105","F070106"],"references":["RC00688","RC00689","RC00690","RC00691","RC00700","RC00701","RC00938","RC00989","RC03606","RC03607","RC03608","RC03609","RC02035","RC02656","RC03277","RC04100","RC04224","RC04348","RC04472","RC04596","RC04777","RC04790","RC04803","RC04816","RC04829","RC04842","RC04855","RC04868"]},{"compound_ID":"D0093","name":"Oxaprozin","synonyms":"oxaprozin; 21256-18-8; Daypro; Alvo; Oxaprozine; Oxaprozinum; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; 3-(4,5-Diphenyloxazol-2-yl)propanoic acid; Deflam; Oxaprozina; Voir; Oxaprozine [INN-French]; Oxaprozinum [INN-Latin]; WY-21743; Oxaprozina [INN-Spanish]; 4,5-Diphenyl-2-oxazolepropionic acid; WY-21,743; 4,5-Diphenyl-2-oxazolepropanoic acid; 2-Oxazolepropanoic acid, 4,5-diphenyl-; WY 21743; NSC310839; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; beta-(4,5-Diphenyloxazol-2-yl)propionic acid; UNII-MHJ80W9LRB; MHJ80W9LRB; NSC 310839; CHEMBL1071; CHEBI:7822; 3-(diphenyl-1,3-oxazol-2-yl)propanoic acid; C18H15NO3; 2-OXAZOLEPROPIONIC ACID, 4,5-DIPHENYL-; OFPXSFXSNFPTHF-UHFFFAOYSA-N; .beta.-(4,5-Diphenyloxazol-2-yl)propionic acid; EINECS 244-296-1; NSC-310839; BRN 1083168; Danoprox; Dayrun; 3-(4,5-Diphenyl-2-oxazolyl)propanoic acid; CAS-21256-18-8; DSSTox_CID_25118; DSSTox_RID_80684; DSSTox_GSID_45118; Actirin; Xopane; SMR000058286; Daypro (TN); SR-01000076053; oxaprosin; Durapro; Duraprost; Oxaprozi; Oxapro; Walix; Oxaprozin, solid; Oxaprozin [USAN:BAN:INN:JAN]; Oxaprozin,(S); MFCD00215977; NCI310839; 4, 5-Diphenyl-2-oxazolepropionic acid; Oxaprozinum;Wy21743; Maybridge1_008800; Prestwick0_001060; Prestwick1_001060; Prestwick2_001060; Prestwick3_001060; Spectrum2_001696; Spectrum3_001078; Spectrum4_001231; Lopac-O-9637; O 9637; SCHEMBL3286; NCIStruc1_000799; NCIStruc2_000787; BIDD:PXR0149; Lopac0_000944; Oprea1_509470; BSPBio_001020; BSPBio_002696; KBioGR_001722; MLS000759535; MLS001424072; BIDD:GT0438; SPECTRUM1505267; SPBio_001652; SPBio_002940; BPBio1_001122; GTPL7252; Oxaprozin (JP17/USAN/INN); DTXSID1045118; CTK7J3117; HMS566H22; HSDB 7586; KBio3_001916; KS-00000ULR; HMS1571C22; HMS1922P17; HMS2051L15; HMS2093O08; HMS2098C22; HMS3262N10; HMS3393L15; HMS3652H17; HMS3715C22; Pharmakon1600-01505267; Wy21743; BCP28431; HY-B0808; Tox21_110059; Tox21_500944; 2-Oxazolepropanoic acid,5-diphenyl-; 2-Oxazolepropionic acid,5-diphenyl-; ANW-63377; BDBM50002861; CCG-36508; NCGC00014711; NSC758949; s4230; SBB053166; ZINC49643479; 4,5-diphenyloxazole-2-propanoic acid; 4,5-Diphenyloxazole-2-propionic acid; AKOS000206807; Oxaprozin [USAN:USP:INN:BAN:JAN]; Tox21_110059_1; CS-7975; DB00991; KS-5196; LP00944; MCULE-7099031811; NC00214; NSC-758949; NCGC00014711-01; NCGC00014711-02; NCGC00014711-03; NCGC00014711-04; NCGC00014711-05; NCGC00014711-06; NCGC00014711-07; NCGC00014711-08; NCGC00014711-09; NCGC00014711-10; NCGC00014711-11; NCGC00014711-14; NCGC00014711-15; NCGC00094249-01; NCGC00094249-02; NCGC00094249-03; NCGC00094249-04; NCGC00094249-05; NCGC00094249-06; NCGC00094249-07; NCGC00261629-01; AC-26512; AK-84489; CPD000058286; NCI60_002681; SAM001246770; SC-13926; SBI-0050918.P002; AB0011812; LS-100216; TC-152122; 3-(4,5-Diphenyl-2-oxazolyl)propionic acid; AB00514024; B1804; EU-0100944; FT-0638104; O0377; ST50949623; SW197319-4; 3-(4, 5-Diphenyl-2-oxazolyl)propenoic acid; EN300-25629; 3-(4,5-Diphenyl-oxazol-2-yl)-propionic acid; 4.5-Diphenyl-2-oxazolepropanoic acid|||Daypro; C07356; D00463; J10396; K-6109; AB00514024_08; AB00514024_09; 256O188; A815225; J-013955; Q1749609; SR-01000076053-1; SR-01000076053-3; SR-01000076053-7; SR-01000076053-9; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid #; BRD-K25394294-001-05-7; BRD-K25394294-001-08-1; Z217102860; Oxaprozin, United States Pharmacopeia (USP) Reference Standard","trade_name":"","abbrev_name":"","description":"","molecular_formula":"C18H15NO3","molecular_weight":"293.3","state":"solid","clearance":"","volume_of_distribution":"* 11 to 17 L/70 kg","route_of_elimination":"Oxaprozin is expected to be excreted in human milk based on its physical-chemical properties; however, the amount of oxaprozin excreted in breast milk has not been evaluated. Approximately 95% of oxaprozin is metabolized by the liver. Approximately 5% of the oxaprozin dose is excreted unchanged in the urine. Sixty-five percent (65%) of the dose is excreted in the urine and 35% in the feces as metabolite.\nBiliary excretion of unchanged oxaprozin is a minor pathway. Several oxaprozin metabolites have been identified in human urine or feces.","protein_binding":">99.5% bound to albumin","half_life":"54.9 hours","absorption":"Oxaprozin is 95% absorbed after oral administration. Food may reduce the rate of absorption of oxaprozin, but the extent of absorption is unchanged. Antacids do not significantly affect the extent and rate of oxaprozin absorption.","cid":"4614","classification":"M","indications":"Arthritis; Juvenile idiopathic arthritis; Osteoarthritis; Rheumatoid arthritis","side_effects":"","atc_codes":"M01AE12","group":"Drug","drug_type":"","target":[],"function":[],"references":[]},{"compound_ID":"D0094","name":"Pentostatin","synonyms":"pentostatin; Deoxycoformycin; Nipent; 53910-25-1; 2'-Deoxycoformycin; Covidarabine; CO-Vidarabine; Pentostatina; Pentostatine; Pentostatinum; Vidarbine; 2'-DCF; Co-V; PD-ADI; UNII-395575MZO7; 2'-Dexoycoformycin; Vira A deaminase inhibitor; YK-176; CI-825; PD-81565; NSC-218321; (R)-Deoxycoformycin; 395575MZO7; (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H,6H,7H,8H-imidazo[4,5-d][1,3]diazepin-8-ol; NCGC00182045-01; 8R-2'-Deoxycoformycin; (R)-2'-Deoxycoformycin; Deaminase inhibitor (PD); dCF; NSC 218321; Pentostatine [INN-French]; Pentostatinum [INN-Latin]; Pentostatina [INN-Spanish]; (8R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol; HSDB 6547; Pentostatin [USAN:INN:BAN:JAN]; BRN 1223097; PD 81565; (R)-3-(2-Deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol; CL 67310465; Deaminase, inhibitor for adenosine arabinoside; Pentostatn; Pentostatin (JAN/USAN/INN); (R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol; (R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol; Pentostatin (PTN); DSSTox_CID_3436; CL-67310465; Pentostatin(Deoxycoformycin); SCHEMBL2817; CHEMBL1580; DSSTox_RID_77027; DSSTox_GSID_23436; BIDD:GT0136; GTPL4805; DTXSID2023436; BDBM22925; Pentostatin, >=95% (HPLC); FPVKHBSQESCIEP-JQCXWYLXSA-N; BDBM223291; HY-A0006; Imidazo(4,5-d)(1,3)diazepin-8-ol, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-, (R)-; ZINC3806262; Tox21_113417; AKOS024456918; AKOS032949742; API0005275; CS-0374; DB00552; PB12063; NCGC00388420-02; Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)-; AB0010579; CAS-53910-25-1; A3708; C02267; D00155; EN300-222177; Q-4464; 910P251; Q425470; SR-01000883935; J-523899; SR-01000883935-1; Z2216208604; (8R)-3-(2-Deoxy-?-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol; (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H,4H,7H,8H-imidazo[4,5-d][1,3]diazepin-8-ol; (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-8-ol; (R,Z)-3-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol","trade_name":"","abbrev_name":"","description":"","molecular_formula":"C11H16N4O4","molecular_weight":"268.27","state":"solid","clearance":"* 68 mL/min/m2","volume_of_distribution":"","route_of_elimination":"In man, following a single dose of 4 mg/m2 of pentostatin infused over 5 minutes, approximately 90% of the dose was excreted in the urine as unchanged pentostatin and/or metabolites as measured by adenosine deaminase inhibitory activity.","protein_binding":"0.04","half_life":"5.7 hours (with a range between 2.6 and 16 hrs)","absorption":"Not absorbed orally, crosses blood brain barrier.","cid":"439693","classification":"L","indications":"Hairy cell leukaemia","side_effects":"Candida infection (0.02); Urogenital disorder (0.15); Abdominal pain; Abscess; Anaemia; Arthralgia; Asthenia; Bacterial infection; Body temperature increased; Bronchitis; Cellulitis; Chills; Conjunctivitis; Cough; Decreased appetite; Dermatitis; Diarrhoea; Dyspnoea; Fatigue; Foetor hepaticus; Gastrointestinal pain; Headache; Hepatocellular injury; Herpes simplex; Herpes zoster; Hyperhidrosis; Hypersensitivity; Infection; Leukopenia; Liver disorder; Liver function test abnormal; Lung disorder; Musculoskeletal discomfort; Myalgia; Nausea; Nervous system disorder; Neurotoxicity; Osteomyelitis; Pain; Pharyngitis; Pneumonia; Pruritus; Rash; Rhinitis; Sepsis; Sinusitis; Skin disorder; Stomatitis; Thrombocytopenia; Upper respiratory tract infection; Viral infection; Vomiting","atc_codes":"L01XX08","group":"Drug","drug_type":"","target":[],"function":[],"references":[]},{"compound_ID":"D0095","name":"Pergolide","synonyms":"pergolide; Permax; Pergolida; 66104-22-1; Pergolidum; Pergolidum [INN-Latin]; Pergolida [INN-Spanish]; Pergolide [INN:BAN]; UNII-24MJ822NZ9; LY-127809; Permax (TN); CHEMBL531; (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline; CHEBI:63617; 24MJ822NZ9; Ergoline, 8-((methylthio)methyl)-6-propyl-, (8beta)-; CHEMBL1275; Pergolide (INN); (2R,4R,7R)-4-[(methylsulfanyl)methyl]-6-propyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene; LY-127,809; NCGC00017366-04; TNP00315; SR-01000721840; Spectrum_001647; Prestwick0_000295; Prestwick1_000295; Prestwick2_000295; Prestwick3_000295; Spectrum2_001970; Spectrum3_001588; Spectrum4_000835; Spectrum5_001649; Biomol-NT_000025; GTPL48; (8beta)-8-[(methylthio)methyl]-6-propylergoline; Lopac0_000984; SCHEMBL26921; BSPBio_000230; BSPBio_003156; KBioGR_001409; KBioSS_002127; cid_47811; BIDD:GT0177; DivK1c_000442; SPBio_002099; SPBio_002449; BPBio1_000254; BPBio1_001211; DTXSID2023438; KBio1_000442; KBio2_002127; KBio2_004695; KBio2_007263; KBio3_002656; LY 141B; NINDS_000442; YEHCICAEULNIGD-MZMPZRCHSA-N; HMS2089C18; BCP18331; ZINC3786466; BDBM50017543; BDBM50028421; CCG-205064; DB01186; IDI1_000442; NCGC00017366-02; NCGC00017366-03; NCGC00017366-05; NCGC00017366-06; NCGC00017366-10; NCGC00142538-01; NCGC00142538-02; NCGC00142538-03; (6aR,9R,10aR)-9-(Methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline; CC-33590; LS-64479; ST057534; SBI-0050957.P003; [2-(1H-Indol-4-yl)-ethyl]-methyl-amine; P2200; C07425; D-8beta-((Methylthio)methyl)-6-propylergoline; D08339; AB00053740-13; AB00053740_14; AB00053740_15; 104P221; C-19410; Q415752; SR-01000721840-8; BRD-K60770992-001-01-8; BRD-K60770992-066-05-2; BRD-K60770992-066-15-1; 9-Methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline; (6aR,9R,10aR)-9-Methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinolin-7-ium; (6aR,9R,10aR)-9-Methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline; 5-Bromo-7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid (10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxo-octahydro-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-amide; 9-Methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinolin-7-ium(Pergolide); 9-Methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline(pergolide); 9-Methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline, mesylate (Pergolide); 9-Methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline; compound with methanesulfonic acid; InChI=1/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s","trade_name":"","abbrev_name":"","description":"","molecular_formula":"C19H26N2S","molecular_weight":"314.5","state":"solid","clearance":"","volume_of_distribution":"","route_of_elimination":"The major route of excretion is the kidney.","protein_binding":"0.9","half_life":"27 hours","absorption":"Significant amount may be absorbed (evidence on bioavailability still lacking).","cid":"47811","classification":"N","indications":"Dyskinesia; Parkinson's disease; Parkinsonism","side_effects":"Acute coronary syndrome (0.011); Personality disorder (0.021); Abdominal pain; Abnormal dreams; Akathisia; Akinesia; Anxiety; Arthralgia; Asthenia; Back pain; Chest pain; Chills; Confusional state; Constipation; Decreased appetite; Depression; Dermatitis; Diarrhoea; Diplopia; Dizziness; Dysgeusia; Dyskinesia; Dyspepsia; Dyspnoea; Extrapyramidal disorder; Eye disorder; Face oedema; Feeling abnormal; Gait disturbance; Gastrointestinal pain; Hallucination; Headache; Hiccups; Hyperhidrosis; Hypertension; Hypertonia; Infection; Influenza; Insomnia; Loss of consciousness; Muscle twitching; Musculoskeletal discomfort; Nausea; Neck pain; Oedema; Oedema peripheral; Orthostatic hypotension; Pain; Paraesthesia; Pollakiuria; Psychotic disorder; Rash; Rhinitis; Shock; Somnolence; Speech disorder; Syncope; Tremor; Urinary tract infection; Visual impairment; Weight increased","atc_codes":"N04BC02","group":"Drug","drug_type":"","target":[],"function":[],"references":[]},{"compound_ID":"D0096","name":"Perhexiline","synonyms":"PERHEXILINE; Perhexilene; 2-(2,2-Dicyclohexylethyl)piperidine; 6621-47-2; Perhexilinum; Perhexilina; Perhexilinum [INN-Latin]; Perhexilina [INN-Spanish]; (+)-2-(2,2-Dicyclohexylethyl)piperidine; (-)-2-(2,2-Dicyclohexylethyl)piperidine; Perhexiline [INN:BAN]; Piperidine, 2-(2,2-dicyclohexylethyl)-; 39648-48-1; EINECS 229-569-5; CHEMBL75880; CHEBI:35553; CYXKNKQEMFBLER-UHFFFAOYSA-N; 39648-47-0; perhexilline; Perhexiline (INN); 2-[2,2-DICYCLOHEXYLETHYL]PIPERIDINE MALEATE SALT; EINECS 252-426-3; EINECS 254-558-7; EINECS 254-559-2; Spectrum_000013; (1)-2-(2,2-Dicyclohexylethyl)piperidine; Prestwick0_000286; Prestwick1_000286; Prestwick2_000286; Prestwick3_000286; Spectrum2_001539; Spectrum3_001579; Spectrum4_000173; Spectrum5_001084; Oprea1_365504; BSPBio_000192; BSPBio_003118; KBioGR_000685; KBioSS_000353; DivK1c_000542; SCHEMBL114894; SPBio_001358; SPBio_002411; BPBio1_000212; DTXSID7023439; BDBM61402; cid_5284439; CTK1C5099; KBio1_000542; KBio2_000353; KBio2_002921; KBio2_005489; KBio3_002618; NINDS_000542; DB01074; MCULE-1263095324; ACM39648470; ACM39648481; IDI1_000542; NCGC00018261-02; NCGC00018261-05; 35193-73-8; (?)-2-(2,2-Dicyclohexylethyl)piperidine; SBI-0051794.P002; LS-176505; AB00053656; D08340; 2-(2,2-dicyclohexylethyl)piperidine;maleic acid; AB00053656_22; Q1232737; (Z)-2-butenedioic acid;2-(2,2-dicyclohexylethyl)piperidine; (Z)-but-2-enedioic acid;2-(2,2-dicyclohexylethyl)piperidine; Piperidine, 2-(2,2-dicyclohexylethyl)-, (2Z)-2-butenedioate (1:1)","trade_name":"","abbrev_name":"","description":"prophylactic antianginal agent; coronary vasodilator","molecular_formula":"C19H35N","molecular_weight":"277.5","state":"solid","clearance":"","volume_of_distribution":"","route_of_elimination":"","protein_binding":"Perhexiline and its metabolites are highly protein bound (>90%).","half_life":"Variable and non-linear. Some reports show a half-life of 2-6 days, others indicate it could be as high as 30 days.","absorption":"Well absorbed (>80%) from the gastrointestinal tract following oral administration.","cid":"4746","classification":"C","indications":"Coronary artery disease; Diabetes mellitus","side_effects":"","atc_codes":"C08EX02","group":"Drug","drug_type":"","target":["T001","T002","T021","T021001","T021002","T022","T027001","T028","T029","T030","T034","T211","T212","T394","T408"],"function":["F010503","F0108","F0201","F02010103","F02010104","F020103","F020104","F020601","F02060101","F02060201","F02110304","F0303"],"references":["RC00811","RC00812","RC00813","RC00814","RC00815","RC00816","RC00817","RC00818","RC00819","RC00820","RC00821","RC00824","RC00825","RC00826","RC00827","RC00828","RC00829","RC00830","RC00831","RC00832","RC00833","RC00834","RC00835","RC00836","RC00838","RC00840","RC00841","RC00842","RC00843","RC00844","RC00845","RC00846","RC00847","RC00848","RC00849","RC00850","RC00851","RC00852","RC00853","RC00854","RC00855","RC00856","RC00857","RC00858","RC00859","RC00860","RC00861","RC00862","RC00863","RC00864","RC00865","RC00866","RC00868","RC00869","RC00872","RC00873","RC00880","RC00945","RC03536","RC03537","RC03547","RC03548","RC03776","RC03819","RC04105","RC04229","RC04353","RC04477","RC04601","RC05005","RC05015","RC05025","RC05039","RC05053"]},{"compound_ID":"D0097","name":"Phenformin","synonyms":"PHENFORMIN; N-Phenethylbiguanide; 114-86-3; Phenformine; Fenformin; Fenformina; Phenethyldiguanide; Pedg; Phenylethylbiguanide; Cronoformin; Fenfoduron; Fenormin; Glukopostin; Phenformix; Debeone; Diabis; Dibiraf; Dibotin; Glyphen; Retardo; Db-retard; beta-PEBG; Lentobetic; Normoglucina; Phenforminum; Azucaps; DB Comb; Debinyl; Feguanide; Insoral; Dibein; 1-Phenethylbiguanide; D Bretard; beta-Phenethylbiguanide; Fenformina [INN-Spanish]; Phenformine [INN-French]; Phenforminum [INN-Latin]; N-(2-Phenylethyl)imidodicarbonimidic diamide; Biguanide, 1-phenethyl-; Imidodicarbonimidic diamide, N-(2-phenylethyl)-; beta-Phenethybiguanide; Phenformin [INN:BAN]; W 32; NCI-C01741; UNII-DD5K7529CE; CCRIS 500; N'-beta-Phenethylformamidinylliminourea; CHEBI:8064; HSDB 3154; N'-beta-Fenetilformamidiniliminourea [Italian]; EINECS 204-057-4; BRN 1977317; N-Phenethylbiguanide hydrochloride; CHEMBL170988; DD5K7529CE; ICFJFFQQTFMIBG-UHFFFAOYSA-N; 2-(N-phenethylcarbamimidoyl)guanidine; Phenformine HCl; 1-(diaminomethylidene)-2-(2-phenylethyl)guanidine; N-(2-phenylethyl)imidodicarbonimidic diamide hydrochloride; Phenformin (BAN); N'-beta-Fenetilformamidiniliminourea; NCGC00016543-01; CAS-834-28-6; amino{imino[(2-phenylethyl)amino]methyl}carboxamidine; Dipar (Salt/Mix); Imidodicarbonimidic diamide, N-(2-phenylethyl)-, hydrochloride; .beta.-PEBG; Meltrol (Salt/Mix); .beta.-Phenethylbiguanide; Prestwick0_000179; Prestwick1_000179; Prestwick2_000179; Prestwick3_000179; SCHEMBL8424; BSPBio_000077; KBioGR_002392; KBioSS_002397; 4-12-00-02472 (Beilstein Handbook Reference); MLS006011899; SPBio_001998; BPBio1_000085; DTXSID1023449; SCHEMBL10325620; SCHEMBL17300524; KBio2_002392; KBio2_004960; KBio2_007528; KBio3_002871; KS-00000EKW; cMAP_000038; HMS3604G03; ALBB-026048; PHENFORMIN (SEE ALSO PHENFORMIN HYDROCHLORIDE 834-28-6); ZINC5851063; BBL010845; BDBM50237608; BDBM50240908; LS-569; SBB072819; STK635703; 1-carbamimidoyl-3-phenethyl-guanidine; AKOS005567415; N'-.beta.-Fenetilformamidiniliminourea; API0009066; DB00914; MCULE-1254555434; TRA0068161; NCGC00016543-02; NCGC00016543-03; NCGC00016543-04; NCGC00016543-05; NCGC00016543-08; CS-11859; M819; N'-.beta.-Phenethylformamidinylliminourea; SMR004703510; SY031759; N-(2-Phenylethyl)dicarbonimidic diamide #; SBI-0206879.P001; N-(2-Phenylethyl)triimidodicarbonic diamide; ST45029292; MFCD00242966 (95%); C07673; D08351; 1-carbamimidamido-N-(2-phenylethyl)methanimidamide; Q753100; N''''-{amino[(2-phenylethyl)imino]methyl}guanidine; BRD-K11399644-003-03-0; N-(2-phenylethyl)imidodicarbonimidic diamide(Phenformin); N''''-[(E)-amino(imino)methyl]-N-(2-phenylethyl)guanidine; N-amino(imino)methyl-N-phenethyliminomethanediamine(Phenformin); 8CV","trade_name":"","abbrev_name":"","description":"Antidiabetics; biguanide hypoglycemic agent","molecular_formula":"C10H15N5","molecular_weight":"205.26","state":"solid","clearance":"","volume_of_distribution":"","route_of_elimination":"","protein_binding":"","half_life":"","absorption":"","cid":"8249","classification":"A","indications":"","side_effects":"","atc_codes":"A10BD01; A10BA01","group":"Drug","drug_type":"","target":["T001","T020","T387","T400"],"function":["F01","F0108","F02010102","F02010103","F02010201","F02010202","F020103","F02040101","F020403","F021201","F05"],"references":["RC00762","RC00763","RC00766","RC00769","RC00772","RC00775","RC00779","RC00783","RC00786","RC00789","RC00792","RC00795","RC00800","RC00805","RC00810","RC00946","RC00991","RC03630","RC04948","RC04981","RC04986","RC04987"]},{"compound_ID":"D0098","name":"Pioglitazone","synonyms":"Pioglitazone; 111025-46-8; Actos; Pioglitazona; Pioglitazonum; Glustin; Zactos; 105355-27-9; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; Duetact; U 72107; Pioglitazone [INN:BAN]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; AD-4833; CHEBI:8228; Pioglitazone (Actos); HSDB 7322; 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; Actos (TN); 105390-47-4; C19H20N2O3S; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U 72107A; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; AK-56326; 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 2,4-thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-; Pioglitazone [BAN:INN]; Piozone; Pioglu; U-72107; 2,4-Thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-, (+-)-; pioglitazone (INN); U72,107A; 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4-thiazolidinedione; SR-01000763737; pioglitazone-actos; 5-({4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione; HS-0047; Spectrum_001623; Spectrum2_001679; Spectrum3_001002; Spectrum4_001130; Spectrum5_001480; Spectrum5_002067; SCHEMBL4121; BSPBio_002723; KBioGR_001619; KBioSS_002103; MLS006011848; SPBio_001897; GTPL2694; DTXSID3037129; CTK5B5876; KBio2_002103; KBio2_004671; KBio2_007239; KBio3_001943; KS-00000XMH; HYAFETHFCAUJAY-UHFFFAOYSA-N; HMS2089H14; HMS3651D09; HMS3712E16; Pharmakon1600-01504401; ACT02635; BCP26474; BBL029068; BDBM50103521; NSC758876; s2590; STL309607; STL373406; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; AKOS015894953; AKOS022109420; AC-1021; API0009130; CCG-220107; CS-1700; DB01132; MCULE-2346786634; NSC-758876; RTX-010718; SB17323; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; NCGC00163128-01; NCGC00163128-02; NCGC00163128-03; NCGC00163128-04; NCGC00163128-05; NCGC00163128-06; NCGC00163128-07; HY-13956; SC-14147; SMR002204015; SBI-0206791.P001; AB0004710; AB1004597; AB2000683; DB-027350; LS-151327; FT-0601906; FT-0645030; ST24044191; SW197561-3; C07675; D08378; J10289; K-0703; AB00698454-10; AB00698454_11; AB00698454_12; AB00698454_13; 355P279; A801204; Q417765; J-002506; J-516181; SR-01000763737-5; BRD-A48430263-003-02-4; BRD-A48430263-003-06-5; 5-[4-[2-(5-ethyl-2-pyridyl) ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[2-(5-ethyl-2-pyridyl)eth-oxy]benzyl]-2,4-thiazolidinedione; 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4thiazolidinedione; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)-thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl-2,4-thiazolidinedione; 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy] phenyl]methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI); 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, (+/-)-; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione; 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-4-hydroxy-1,3-thiazol-2(5H)-one; [( inverted exclamation markA)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochlorid; [()-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochlorid","trade_name":"Actos","abbrev_name":"","description":"anti-diabetic thiazolidinediones (TZDs); medication used to treat type 2 diabetes","molecular_formula":"C19H20N2O3S","molecular_weight":"356.4","state":"solid","clearance":"The apparent clearance of orally administered pioglitazone is 5 - 7 L/h [FDA Label].","volume_of_distribution":"0.63 ± 0.41 L/kg [FDA Label]","route_of_elimination":"Following oral administration, approximately 15% to 30% of the pioglitazone dose is recovered in the urine. Renal elimination of pioglitazone is negligible, and the drug is excreted primarily as metabolites and their conjugates. It is presumed that most of the oral dose is excreted into the bile either unchanged or as metabolites and eliminated in the feces [FDA Label].","protein_binding":"Pioglitazone is extensively protein bound (> 99%) in human serum, principally to serum albumin. Pioglitazone also binds to other serum proteins, but with lower affinity [FDA Label].","half_life":"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].","absorption":"Following oral administration of pioglitazone, peak concentrations of pioglitazone were observed within 2 hours. Food slightly delays the time to peak serum concentration (T max) to 3 to 4 hours, but does not alter the extent of absorption (AUC). Steady state concentrations are achieved after 7 days of once daily administration of pioglitazone [FDA Label].","cid":"4829","classification":"A","indications":"Anovulatory cycle; Carcinogenicity; Cardiac disorder; Cardiac failure; Cardiac failure congestive; Diabetes mellitus; Diabetic ketoacidosis; Foetor hepaticus; Hepatocellular injury; Insulin resistance; Liver disorder; Macroangiopathy; Type 1 diabetes mellitus; Type 2 diabetes mellitus; Weight decreased","side_effects":"Cardiac disorder (0); Ischaemia (0); Abdominal pain upper; Arthralgia; Asthenia; Back pain; Bronchitis; Cardiac failure; Cardiac failure congestive; Chest pain; Diabetes mellitus; Diarrhoea; Discomfort; Fatigue; Feeling abnormal; Gastroenteritis; Headache; Hypoglycaemia; Ill-defined disorder; Influenza; Injury; Malaise; Muscle spasms; Musculoskeletal discomfort; Myalgia; Oedema; Oedema peripheral; Pain in extremity; Pharyngitis; Respiratory tract infection; Sinusitis; Tooth abscess; Tooth disorder; Upper respiratory tract infection; Urinary tract infection; Visual impairment; Weight increased","atc_codes":"A10BD05; A10BG03; A10BD09; A10BD06; A10BD12","group":"Drug","drug_type":"","target":["T001","T004"],"function":["F01","F010401","F02010103","F02010201","F02010202","F020103","F020401","F02040101","F020403","F02110302"],"references":["RC00554","RC00555","RC00562","RC00563","RC00881","RC00882","RC00883","RC00947","RC00948","RC03633","RC04874","RC04967","RC04971","RC04972","RC04976","RC04980","RC04984","RC04985"]},{"compound_ID":"D0099","name":"Piroxicam","synonyms":"piroxicam; 36322-90-4; Feldene; Piroxicamum; Pyroxycam; Roxicam; Piroftal; BAXO; Roxam; CP 16171; CP-16171; Piroxicamum [INN-Latin]; CHF 1251; UNII-13T4O6VMAM; 4-Hydroxy-2-methyl-N-(pyridin-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide; NSC 666076; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; Piroxicam (Feldene); CCRIS 3719; C15H13N3O4S; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; EINECS 252-974-3; BRN 0627692; 13T4O6VMAM; 4-Hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2H-1,2-benzothiazine 1,1-dioxide; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; MLS000069644; CHEBI:8249; QYSPLQLAKJAUJT-UHFFFAOYSA-N; NSC666076; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid [German]; 4-hydroxy-2-methyl-N-pyridin-2-yl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; NCGC00015823-02; Artroxicam; Bruxicam; Caliment; Flogobene; Geldene; Improntal; Larapam; Piroflex; Reudene; Roxiden; Sasulen; SMR000035997; Solocalm; Erazon; Pirkam; piroxicam usp; Riacen; Zunden; CAS-36322-90-4; DSSTox_CID_1170; DSSTox_RID_75990; DSSTox_GSID_21170; Rosiden; Felden; Feldene Fast; Feldene Gel; (4-hydroxy-2-methyl-1,1-dioxobenzo[e]1,2-thiazin-3-yl)-N-(2-pyridyl)carboxamid e; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-Dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; (Z)-3-(hydroxy(pyridin-2-ylamino)methylene)-2-methyl-2H-benzo[e][1,2]thiazin-4(3H)-one 1,1-dioxide; 1488516-58-0; Feldene (TN); Piroxicam [USAN:BAN:INN:JAN]; SR-01000000199; AK1015; Roxam;Feldene; 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1?^{6},2-benzothiazine-3-carboxamide; Piroxicam,(S); Piroxicam(Feldene); Prestwick_573; Piroxicam [USAN:USP:INN:BAN:JAN]; piroxicam:malonic acid; Spectrum_001115; Tocris-0960; Opera_ID_442; Piroxicam: Form Alpha1; Piroxicam: Form Alpha2; Prestwick0_000211; Prestwick1_000211; Prestwick2_000211; Prestwick3_000211; Spectrum2_001287; Spectrum3_000780; Spectrum4_000968; Spectrum5_001445; Lopac-P-5654; CHEMBL527; P 5654; BIDD:PXR0154; Lopac0_000900; Oprea1_714707; SCHEMBL13462; SCHEMBL21350; BSPBio_000221; BSPBio_001030; BSPBio_002460; KBioGR_000370; KBioGR_001315; KBioSS_000370; KBioSS_001595; MLS000038002; MLS001148207; MLS001304054; MLS004774122; DivK1c_000369; SPECTRUM1500491; SPBio_001293; SPBio_002142; Piroxicam (JP17/USP/INN); BPBio1_000245; GTPL7273; Piroxicam, >=98% (TLC); SCHEMBL3703617; Piroxicam for system suitability; CHEMBL1518938; DTXSID5021170; BCBcMAP01_000176; BDBM85245; CTK7I2700; HMS501C11; KBio1_000369; KBio2_000370; KBio2_001595; KBio2_002938; KBio2_004163; KBio2_005506; KBio2_006731; KBio3_000719; KBio3_000720; KBio3_001680; KS-00000JBT; NINDS_000369; Piroxicam 1.0 mg/ml in Methanol; Bio1_000363; Bio1_000852; Bio1_001341; Bio2_000355; Bio2_000835; HMS1362D11; HMS1568L03; HMS1792D11; HMS1920H22; HMS1990D11; HMS2089B06; HMS2092A05; HMS2095L03; HMS2231G03; HMS3262D22; HMS3267I03; HMS3369B07; HMS3403D11; HMS3414H17; HMS3429L03; HMS3655C04; HMS3678H15; HMS3712L03; Pharmakon1600-01500491; BCP02919; HY-B0253; NSC_4856; Tox21_110231; Tox21_200151; Tox21_500900; ANW-43611; BBL016493; CCG-36403; MFCD00057317; NSC757284; s1713; STK177288; ZINC12466469; ZINC51133897; ZINC87724780; AKOS000714958; AKOS025312555; AKOS026749939; Tox21_110231_1; AM84917; CS-2233; DB00554; KS-5322; LP00900; LS-7663; MCULE-1939282084; NSC-666076; NSC-757284; (4-Hydroxy-2-methyl-1,1-dioxobenzo[e]1,2-thiazin-3-yl)-N-(2-pyridyl)carboxamide; 3,4-Dihydro-2-methyl-4-oxo-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1lambda6,2-benzothiazine-3-carboxamide; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; IDI1_000369; IDI1_002110; NCGC00015823-01; NCGC00015823-03; NCGC00015823-04; NCGC00015823-05; NCGC00015823-06; NCGC00015823-07; NCGC00015823-08; NCGC00015823-09; NCGC00015823-10; NCGC00015823-11; NCGC00015823-12; NCGC00015823-13; NCGC00015823-14; NCGC00015823-15; NCGC00015823-17; NCGC00015823-18; NCGC00021244-03; NCGC00021244-05; NCGC00021244-06; NCGC00021244-07; NCGC00021244-08; NCGC00021244-09; NCGC00188982-01; NCGC00257705-01; NCGC00261585-01; AC-24190; NCI60_022912; SC-16825; ST069379; BCP0726000299; SBI-0050875.P004; AB0011706; AB2000240; CAS_36322-90-4; CP-16,171; Piroxicam, meets USP testing specifications; ST2411449; TR-014899; EU-0100900; FT-0080892; FT-0630590; P1905; SW219862-1; EN300-70724; A19556; C01608; D00127; J10253; M-9898; AB00052074-21; AB00052074-22; AB00052074_23; AB00052074_24; 322P904; Q408676; SR-01000000199-3; SR-01000000199-5; SR-01000000199-9; W-106626; SR-01000000199-12; F0001-2399; Piroxicam, British Pharmacopoeia (BP) Reference Standard; Z1259192069; Piroxicam, European Pharmacopoeia (EP) Reference Standard; Piroxicam, United States Pharmacopeia (USP) Reference Standard; Piroxicam, Pharmaceutical Secondary Standard; Certified Reference Material; 2H-1,2-Benzothiazine-3-carboxamide,4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 4-hydroxy-2-methyl-1,1-dioxo-N-(2-pyridyl)-1$l^{6},2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1$l^{6},2-benzothiazine-3-carboxamide; 4-Hydroxy-2-methyl-3-(2-pyridylcarbamoyl)-2H-1,2-benzothiazine 1,1-Dioxide; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzo-thiazine-3-carboxamide1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide1,1-dioxide; N-(2-pyridyl)-4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; (E)-3-(hydroxy(pyridin-2-ylamino)methylene)-2-methyl-2,3-dihydro-4H-benzo[e][1,2]thiazin-4-one 1,1-dioxide; 1044566-76-8; 3-[hydroxy(pyridin-2-ylamino)methylidene]-2-methyl-2,3-dihydro-4h-1,2-benzothiazin-4-one 1,1-dioxide; 3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2H-1$l^{6},2-benzothiazine-1,1,4-trione; 3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2H-1lambda,2-benzothiazine-1,1,4-trione; 3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2H-1lambda6,2-benzothiazine-1,1,4-trione; 4-hydroxy-2-methyl-1,1-dioxo-N-(2-pyridyl)-1,2-dihydro-1lambda,2-benzothiazine-3-carboxamide; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine -3-carboxamide-1,1-dioxide malonic acid","trade_name":"Feldene","abbrev_name":"Piroksikam, piroxikam","description":"nonsteroidal anti-inflammatory drug of the oxicam class","molecular_formula":"C15H13N3O4S","molecular_weight":"331.3","state":"solid","clearance":"","volume_of_distribution":"* 0.14 L/kg","route_of_elimination":"Piroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a piroxicam dose is excreted unchanged. However, a substantial portion of piroxicam elimination occurs by hepatic metabolism. Piroxicam is excreted into human milk.","protein_binding":"","half_life":"30 to 86 hours","absorption":"Well absorbed following oral administration.","cid":"54676228","classification":"S; M","indications":"Ankylosing spondylitis; Arthritis; Ligament sprain; Osteoarthritis; Rheumatoid arthritis; Soft tissue injury; Tendonitis","side_effects":"Abdominal discomfort (0.057); Stomatitis (0.01)","atc_codes":"M01AC01; M02AA07; S01BC06","group":"Drug","drug_type":"","target":["T001","T002","T408"],"function":["F01","F0108","F0201","F02010102","F02010103","F0206","F0221","F0303","F0504","F070105","F070106"],"references":["RC02084","RC02705","RC03326","RC04108","RC04232","RC04356","RC04480","RC04604","RC04770","RC04783","RC04796","RC04809","RC04822","RC04835","RC04848","RC04861"]},{"compound_ID":"D0100","name":"Porfiromycin","synonyms":"Porfiromycin; Methylmitomycin; Methyl mitomycin C; Regamycin; N-Methylmitomycin C; ENT-50825; Nsc 56410; 801-52-5; Porfiromycine [INN-French]; Porfiromycinum [INN-Latin]; UNII-H1WK901OA6; Porphyromycin; Porfiromicina [INN-Spanish]; Porfiromycin [USAN:INN:BAN]; U-14743; NSC-56410; AI3-50825; H1WK901OA6; Mitomycin C, N-methyl-; C16H20N4O5; 6-Amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-1,5-dimethylazirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione carbamate (ester); Porfiromicina; Porfiromycinum; Methylmitomycin C; Azirino(2',3':3,4)pyrrolo(1,2-a)-indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-1,5-dimethyl-; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-1,5-dimethyl-, carbamate (ester); Porfiromycin (USAN/INN); SCHEMBL5046; CHEMBL521078; ZINC100091597; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-1,5-dimethyl-, (1aS-(1aalpha,8beta,8aalpha,8balpha))-; LS-23381; D05572; U-14,743; (amino-methoxy-dimethyl-dioxo-[?]yl)methyl carbamate; Q27279527; 6-Amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-1,5-dimethyl-azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, carbamate ester; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a- methoxy-1,5-dimethyl-, carbamate (ester); Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a- methoxy-1,5-dimethyl-, carbamate (ester) (8CI); Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b- hexahydro-8a-methoxy-1,5-dimethyl-,(1aR-(1aalpha,8beta,8aalpha,8balpha))-; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b- hexahydro-8a-methoxy-1,5-dimethyl-,(1aR-(1aalpha,8beta,8aalpha,8balpha))- (9CI)","trade_name":"","abbrev_name":"","description":"","molecular_formula":"C16H20N4O5","molecular_weight":"348.35","state":"solid","clearance":"","volume_of_distribution":"","route_of_elimination":"","protein_binding":"","half_life":"","absorption":"","cid":"13116","classification":"Others","indications":"","side_effects":"","atc_codes":"","group":"Drug","drug_type":"","target":[],"function":[],"references":[]}]}